<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome - Jacobsen, A - 2022 | Cochrane Library</title> <meta content="Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome - Jacobsen, A - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013130.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome - Jacobsen, A - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013130.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013130.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome" name="citation_title"/> <meta content="Audrey Jacobsen" name="citation_author"/> <meta content="University of Minnesota Medical School" name="citation_author_institution"/> <meta content="Bayanne Olabi" name="citation_author"/> <meta content="Lothian University Hospitals NHS Trust, Lauriston Building" name="citation_author_institution"/> <meta content="Annie Langley" name="citation_author"/> <meta content="The Ottawa Hospital and the University of Ottawa" name="citation_author_institution"/> <meta content="Jennifer Beecker" name="citation_author"/> <meta content="The Ottawa Hospital and the University of Ottawa" name="citation_author_institution"/> <meta content="Eric Mutter" name="citation_author"/> <meta content="The Ottawa Hospital" name="citation_author_institution"/> <meta content="Amanda Shelley" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Brandon Worley" name="citation_author"/> <meta content="Timothy Ramsay" name="citation_author"/> <meta content="Ottawa Hospital Research Institute" name="citation_author_institution"/> <meta content="Arturo Saavedra" name="citation_author"/> <meta content="University of Virginia Health System" name="citation_author_institution"/> <meta content="Roses Parker" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust Second Floor, OUH Cowley Unipart House Business Centre" name="citation_author_institution"/> <meta content="Fiona Stewart" name="citation_author"/> <meta content="The University of Liverpool" name="citation_author_institution"/> <meta content="Jordi Pardo Pardo" name="citation_author"/> <meta content="Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus" name="citation_author_institution"/> <meta content="jpardo@uottawa.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD013130.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/03/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013130.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013130.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013130.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetylcysteine; Adrenal Cortex Hormones [therapeutic use]; *Autoimmune Diseases [drug therapy]; Cyclosporine [therapeutic use]; Etanercept; Immunoglobulins, Intravenous [therapeutic use]; Observational Studies as Topic; *Stevens-Johnson Syndrome [drug therapy]; Thalidomide; Tumor Necrosis Factor-alpha" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013130.pub2&amp;doi=10.1002/14651858.CD013130.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013130\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013130\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013130.pub2",title:"Systemic interventions for treatment of Stevens\\u2010Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome",firstPublishedDate:"Mar 11, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013130.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013130.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013130.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013130.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013130.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013130.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013130.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013130.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013130.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013130.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15103 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013130.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/appendices#CD013130-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/supinfo/CD013130StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/supinfo/CD013130StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0004">Audrey Jacobsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0005">Bayanne Olabi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0006">Annie Langley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0007">Jennifer Beecker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0008">Eric Mutter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0009">Amanda Shelley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0010">Brandon Worley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0011">Timothy Ramsay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0012">Arturo Saavedra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0013">Roses Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0014">Fiona Stewart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information#CD013130-cr-0015"><i class="icon corresponding-author fa fa-envelope"></i>Jordi Pardo Pardo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information/en#CD013130-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 March 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013130.pub2">https://doi.org/10.1002/14651858.CD013130.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013130-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013130-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013130-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013130-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013130-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013130-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013130-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013130-abs-0001" lang="en"> <section id="CD013130-sec-0001"> <h3 class="title" id="CD013130-sec-0001">Background</h3> <p>Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare, severe cutaneous adverse reactions usually triggered by medications. In addition to tertiary‐level supportive care, various systemic therapies have been used including glucocorticoids, intravenous immunoglobulins (IVIGs), cyclosporin, N‐acetylcysteine, thalidomide, infliximab, etanercept, and plasmapheresis. There is an unmet need to understand the efficacy of these interventions. </p> </section> <section id="CD013130-sec-0002"> <h3 class="title" id="CD013130-sec-0002">Objectives</h3> <p>To assess the effects of systemic therapies (medicines delivered orally, intramuscularly, or intravenously) for the treatment of SJS, TEN, and SJS/TEN overlap syndrome. </p> </section> <section id="CD013130-sec-0003"> <h3 class="title" id="CD013130-sec-0003">Search methods</h3> <p>We searched the following databases up to March 2021: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase. We also searched five clinical trial registers, the reference lists of all included studies and of key review articles, and a number of drug manufacturer websites. We searched for errata or retractions of included studies. </p> </section> <section id="CD013130-sec-0004"> <h3 class="title" id="CD013130-sec-0004">Selection criteria</h3> <p>We included only randomised controlled trials (RCTs) and prospective observational comparative studies of participants of any age with a clinical diagnosis of SJS, TEN, or SJS/TEN overlap syndrome. We included all systemic therapies studied to date and permitted comparisons between each therapy, as well as between therapy and placebo. </p> </section> <section id="CD013130-sec-0005"> <h3 class="title" id="CD013130-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as specified by Cochrane. Our primary outcomes were SJS/TEN‐specific mortality and adverse effects leading to discontinuation of SJS/TEN therapy. Secondary outcomes included time to complete re‐epithelialisation, intensive care unit length of stay, total hospital length of stay, illness sequelae, and other adverse effects attributed to systemic therapy. We rated the certainty of the evidence for each outcome using GRADE. </p> </section> <section id="CD013130-sec-0006"> <h3 class="title" id="CD013130-sec-0006">Main results</h3> <p>We included nine studies with a total of 308 participants (131 males and 155 females) from seven countries. We included two studies in the quantitative meta‐analysis. </p> <p>We included three RCTs and six prospective, controlled observational studies. Sample sizes ranged from 10 to 91. Most studies did not report study duration or time to follow‐up. Two studies reported a mean SCORe of Toxic Epidermal Necrosis (SCORTEN) of 3 and 1.9. Seven studies did not report SCORTEN, although four of these studies reported average or ranges of body surface area (BSA) (means ranging from 44% to 51%). Two studies were set in burns units, two in dermatology wards, one in an intensive care unit, one in a paediatric ward, and three in unspecified inpatient units. Seven studies reported a mean age, which ranged from 29 to 56 years. Two studies included paediatric participants (23 children). </p> <p>We assessed the results from one of three RCTs as low risk of bias in all domains, one as high, and one as some concerns. We judged the results from all six prospective observational comparative studies to be at a high risk of bias. We downgraded the certainty of the evidence because of serious risk of bias concerns and for imprecision due to small numbers of participants. </p> <p>The interventions assessed included systemic corticosteroids, tumour necrosis factor‐alpha (TNF‐alpha) inhibitors, cyclosporin, thalidomide, N‐acetylcysteine, IVIG, and supportive care. No data were available for the main comparisons of interest as specified in the review protocol: etanercept versus cyclosporin, etanercept versus IVIG, IVIG versus supportive care, IVIG versus cyclosporin, and cyclosporin versus corticosteroids. </p> <p><b>Corticosteroids versus no corticosteroids</b> </p> <p>It is uncertain if there is any difference between corticosteroids (methylprednisolone 4 mg/kg/day for two more days after fever had subsided and no new lesions had developed) and no corticosteroids on disease‐specific mortality (risk ratio (RR) 2.55, 95% confidence interval (CI) 0.72 to 9.03; 2 studies; 56 participants; very low‐certainty evidence). Time to complete re‐epithelialisation, length of hospital stay, and adverse effects leading to discontinuation of therapy were not reported. </p> <p><b>IVIG versus no IVIG</b> </p> <p>It is uncertain if there is any difference between IVIG (0.2 to 0.5 g/kg cumulative dose over three days) and no IVIG in risk of disease‐specific mortality (RR 0.33, 95% CI 0.04 to 2.91); time to complete re‐epithelialisation (mean difference (MD) −2.93 days, 95% CI −4.4 to −1.46); or length of hospital stay (MD −2.00 days, 95% CI −5.81 to 1.81). All results in this comparison were based on one study with 36 participants, and very low‐certainty evidence. Adverse effects leading to discontinuation of therapy were not reported. </p> <p><b>Etanercept (TNF‐alpha inhibitor) versus corticosteroids</b> </p> <p>Etanercept (25 mg (50 mg if weight &gt; 65 kg) twice weekly "until skin lesions healed") may reduce disease‐specific mortality compared to corticosteroids (intravenous prednisolone 1 to 1.5 mg/kg/day "until skin lesions healed") (RR 0.51, 95% CI 0.16 to 1.63; 1 study; 91 participants; low‐certainty evidence); however, the CIs were consistent with possible benefit and possible harm. Serious adverse events, such as sepsis and respiratory failure, were reported in 5 of 48 participants with etanercept and 9 of 43 participants with corticosteroids, but it was not clear if they led to discontinuation of therapy. Time to complete re‐epithelialisation and length of hospital stay were not reported. </p> <p><b>Cyclosporin versus IVIG </b> </p> <p>It is uncertain if there is any difference between cyclosporin (3 mg/kg/day or intravenous 1 mg/kg/day until complete re‐epithelialisation, then tapered off (10 mg/day reduction every 48 hours)) and IVIG (continuous infusion 0.75 g/kg/day for 4 days (total dose 3 g/kg) in participants with normal renal function) in risk of disease‐specific mortality (RR 0.13, 95% CI 0.02 to 0.98, 1 study; 22 participants; very low‐certainty evidence). Time to complete re‐epithelialisation, length of hospital stay, and adverse effects leading to discontinuation of therapy were not reported. </p> <p>No studies measured intensive care unit length of stay.</p> </section> <section id="CD013130-sec-0007"> <h3 class="title" id="CD013130-sec-0007">Authors' conclusions</h3> <p>When compared to corticosteroids, etanercept may result in mortality reduction. For the following comparisons, the certainty of the evidence for disease‐specific mortality is very low: corticosteroids versus no corticosteroids,  IVIG versus no IVIG and cyclosporin versus IVIG. There is a need for more multicentric studies, focused on the most important clinical comparisons, to provide reliable answers about the best treatments for SJS/TEN. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013130-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013130-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013130-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013130-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013130-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013130-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013130-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013130-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013130-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013130-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013130-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013130-abs-0002" lang="en"> <h3>Which treatments that affect the whole body work best to treat severe skin reactions (Stevens‐Johnson syndrome and toxic epidermal necrolysis)? </h3> <p><b>Key messages</b> </p> <p>Treating severe skin reactions with etanercept (a medicine that acts to reduce a specific part of the immune system), rather than steroids (which broadly reduces the immune system), may result in a lower number of deaths from Stevens‐Johnson syndrome and toxic epidermal necrolysis. </p> <p>We are uncertain about the effectiveness of other treatments, such as steroids and cyclosporin (medicines that act on the immune system) or immunoglobulins (naturally produced antibodies). We need more studies set across multiple sites that compare the effectiveness and safety of the most important treatments. </p> <p><b>What causes severe skin reactions?</b> </p> <p>Certain medications may trigger severe skin reactions known as Stevens‐Johnson syndrome (SJS), a more severe condition known as toxic epidermal necrolysis (TEN), or an overlap syndrome (SJS/TEN). Large skin blisters form, which leave painful sores. The affected skin eventually peels off (necrosis). Cases are rare, but can be fatal if they lead to infections or problems affecting other organs. </p> <p>Severe skin reactions are medical emergencies, and require treatment in a hospital, often in an intensive care or a burns unit. Treatments include supportive care, such as fluids and nutrition, wound care, and painkilling medications. </p> <p><b>What did we want to find out?</b> </p> <p>In addition to supportive care, treatments taken by mouth or injected include medicines that act on the immune system (e.g. etanercept) and intravenous immunoglobulins (antibodies). </p> <p>We wanted to find out how well these treatments work to treat severe skin reactions.</p> <p><b>What did we do?</b> </p> <p>We searched for studies of all currently used treatments taken by mouth or injected to treat SJS, TEN, or SJS/TEN overlap. We were interested in studies that compared one of these treatments against another, or against supportive treatment alone to determine whether one worked better than the other.  </p> <p><b>What did we find?</b> </p> <p>We found 9 studies in 308 people (adults and a few children), which took place in India, Europe, China, and Taiwan. We found three randomised controlled trials (RCTs) (a type of study where participants are randomly assigned to one of two or more treatment groups). The other six studies observed the effectiveness of a treatment compared to another, without randomly assigning participants to a treatment (observational study). Most patients in the studies (where reported) had a moderate severity of disease, with 44% to 51% of their body surface area affected by rash. Studies were set in burn units, intensive care units and inpatient hospital wards.  </p> <p><b>Main results</b> </p> <p>The evidence comparing no steroids to steroids came from only 2 observational studies in 56 people; we are uncertain about this result due to our lack of confidence in the evidence: on average, out of 1000 people given steroids, 232 people are at risk of dying, compared with 91 out of every 1000 not given steroids. The number of days to full skin healing and length of hospital stay were not reported. </p> <p>The evidence comparing immunoglobulins to no immunoglobulins came from 1 observational study in 36 people; we are uncertain about these results due to our lack of confidence in the evidence: on average, for every 1000 people given immunoglobulins, 55 people are at risk of dying, compared with 167 of every 1000 people not given immunoglobulins. The skin of people given immunoglobulins healed almost three days faster, and people spent two days less in hospital. </p> <p>Compared with steroids, etanercept may reduce the number of people who die: on average, for every 1000 people given etanercept, 83 people would die from complications of their severe skin reaction (usually infection), compared with 163 out of every 1000 people given steroids (evidence from 1 RCT in 91 participants). Unwanted side effects (such as breathing problems or severe infections) occurred in both etanercept and steroids study groups, but it was not clear if they caused participants to stop treatment. Other studies did not report on unwanted effects leading to discontinuation of treatment. The number of days to full skin healing and length of hospital stay were not reported. </p> <p>The evidence comparing cyclosporin with immunoglobulins was from 1 observational study in 22 people; we are uncertain about this result due to our lack of confidence in the evidence: on average, for every 1000 people given cyclosporin, 65 people are at risk of dying, compared with 500 out of every 1000 people given immunoglobulins. The number of days to full skin healing and length of hospital stay were not reported. </p> <p>No studies measured the length of stay in intensive care units.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are not confident in our results because they came from few studies with small numbers of participants. In most studies, the way in which the studies were conducted could have influenced the findings of the study. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is current to March 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013130-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013130-sec-0090"></div> <h3 class="title" id="CD013130-sec-0091">Implications for practice</h3> <section id="CD013130-sec-0091"> <p>We did not find any studies addressing our most important comparisons: etanercept versus cyclosporin, etanercept versus intravenous immunoglobulin (IVIG), cyclosporin versus corticosteroids, or IVIG versus cyclosporin. </p> <p>Compared to corticosteroids, etanercept may result in a reduction in mortality; however, the 95% CIs are consistent with possible benefit and possible harm (low‐certainty evidence). Although serious adverse events, such as sepsis and respiratory failure, were reported in both treatment groups, it was not clear if they led to discontinuation of therapy. Only one other study reported on adverse events, finding that bacterial infections were the most common complication encountered overall. The study also qualitatively reported other adverse events, but did not confirm in which treatment group the complications had occurred. </p> <p>The evidence is very uncertain (very low‐certainty evidence) for the outcome of mortality for the comparisons corticosteroids versus no corticosteroids, IVIG versus no IVIG, and cyclosporin versus IVIG. </p> <p>The following outcomes were reported for the comparison IVIG versus no IVIG, but very low‐certainty evidence means we are uncertain about the results: </p> <p> <ul id="CD013130-list-0017"> <li> <p>time to complete re‐epithelialisation;</p> </li> <li> <p>length of hospital stay.</p> </li> </ul> </p> <p>This comparison did not report adverse effects leading to discontinuation of Stevens‐Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) therapy. </p> <p>The following outcomes were not reported by the comparisons corticosteroids versus no corticosteroids and cyclosporin versus IVIG: </p> <p> <ul id="CD013130-list-0018"> <li> <p>time to complete re‐epithelialisation;</p> </li> <li> <p>length of hospital stay;</p> </li> <li> <p>adverse effects leading to discontinuation of SJS/TEN therapy.</p> </li> </ul> </p> <p>The following outcomes were not reported by the comparison etanercept versus corticosteroids:</p> <p> <ul id="CD013130-list-0019"> <li> <p>time to complete re‐epithelialisation;</p> </li> <li> <p>length of hospital stay.</p> </li> </ul> </p> <p>None of the included studies measured intensive care unit (ICU) length of stay.</p> <p>The treatment of SJS/TEN varies widely across institutions, and mortality remains high. Etanercept, a tumour necrosis factor‐alpha inhibitor, has emerged as a potential treatment option for people with SJS/TEN. However, the availability and cost may limit its use in resource‐poor settings. </p> </section> <h3 class="title" id="CD013130-sec-0092">Implications for research</h3> <section id="CD013130-sec-0092"> <p>Limitations to this review include the high risk of bias, selection bias, lack of controlling for confounders in the various studies as well as wide confidence intervals. There is a need for randomised studies, with more participants to reach optimal information size. The optimal information size will depend on SCORe of Toxic Epidermal Necrosis (SCORTEN) scores; for example, in people with scores ≥ 5, to detect a 10% reduction in mortality with 80% power and alpha 0.05, 398 participants would be needed. For SCORTEN scores 0 to 1, 2872 participants would be needed to detect a 50% reduction in mortality, with 80% power and alpha 0.05.  </p> <p>Given the rarity of SJS/TEN, this may be difficult to achieve with single‐centre studies. Larger collaborative, multicentric studies are needed to provide more definitive evidences for the main comparisons considered in this review. In particular, studies are needed comparing cyclosporin, etanercept, IVIG, and corticosteroids to one another, including their effect on mortality, adverse effects, length of time in an ICU, and time to re‐epithelialisation. These outcomes were inconsistently reported in the studies included in this review. There is one ongoing study evaluating cyclosporin versus etanercept versus best supportive care that is adequately powered. Trials for the other comparisons will help to provide a complete view of all treatment options.  </p> <p>Additionally, severity of disease is a critical factor in the prediction of mortality in SJS/TEN. For improved comparison, consistent reporting of validated disease severity scores, such as SCORTEN, are needed. Implementing Core Outcome Sets, with validated scoring systems such as SCORTEN, so that subgroup analyses can be made, is critical for future studies of SJS/TEN. Reporting results for age groups where the risk‐benefit ratio might change (i.e. ≥ 75 years) will improve the applicability of the findings.  </p> <p>Finally, clinicians must rely on medical history, clinical morphology, and histopathology, as there are no validated biomarkers to aid in the diagnosis or prognostication of SJS/TEN. It is important to also report baseline comorbidities of the patients included. An adequate description of supportive care and other co‐interventions is necessary to improve the interpretability of the results in different settings.  </p> <p>Further research on the association of human leukocyte antigens, cytochrome P450 isoforms, and inflammatory markers associated with SJS/TEN is warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013130-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013130-sec-0008"></div> <div class="table" id="CD013130-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Corticosteroids compared to no corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Corticosteroids compared to no corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: corticosteroids and supportive care </p> <p><b>Comparison</b>: supportive care<sup>1</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality ‐ SJS and TEN </b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> (65 to 821)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.55</b> </p> <p>(0.72 to 9.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (2 observational studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯ VERY LOW <sup>a,b</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effect estimates calculated from 1 study (<a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>). A second study did not report any events (<a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> – not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay </b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> – not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> – not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1</sup> Supportive care process in 1 study was not described (<a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>). In the second study this was described in detail and includes topical saline compresses and sprays, petroleum jelly, bathing, topical lidocaine gel to the oral mucosa and topical antibiotics and artificial tears to the eyes (<a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>).  </p> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of selection bias and lack of control of any confounding variables.<br/><sup>b</sup>Downgraded two levels for imprecision, as results only based on small studies, and the confidence interval includes serious harms and an important benefit. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013130-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous immunoglobulin (IVIG) compared to no IVIG</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) compared to no IVIG for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: IVIG and supportive care<sup>1</sup> </p> <p><b>Comparison</b>: supportive care<sup>1</sup>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SJS/TEN‐specific mortality</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(6 to 386) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.04 to 2.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An additional observational study, <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, that included a comparison of IVIG with steroids versus steroids alone did not provide useable data for meta‐analysis, but reported that “SCOR‐TEN (Score of Toxic Epidermal Necrosis) analysis showed that treatment with steroids led to an increased mortality rate, whereas treatment with IVIg decreased it". </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time to complete re‐epithelialisation was <b>10.93</b> days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>2.93 days lower</b><br/>(4.4 lower to 1.46 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An additional observational study, <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, included a comparison of IVIG with steroids versus steroids alone did not provide useable data for meta‐analysis, but reported that “The average time for complete re‐epithelialization and hospitalization was lowest in patients given IVIg and highest in those given steroids”. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>‐</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean total hospital length of stay was <b>15.33</b> days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>2.00 days lower</b><br/>(5.81 lower to 1.81 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An additional observational study, <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, that included a comparison of IVIG with steroids versus steroids alone did not provide useable data for meta‐analysis, but reported that “The average time for complete re‐epithelialization and hospitalization was lowest in patients given IVIg and highest in those given steroids”. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1 </sup> <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> compared IVIG plus corticosteroids to supportive care plus corticosteroids.  </p> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of selection bias, as the studies were not randomised and prespecified confounders were not properly addressed, and performance bias.<br/><sup>b</sup>Downgraded two levels due to imprecision, as the confidence interval includes harms and important benefits, and results were from one small study.<br/><sup>c</sup>Downgraded one level due to imprecision, as results were from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013130-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Etanercept compared to no etanercept</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to no etanercept for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: etanercept and supportive care </p> <p><b>Comparison</b>: supportive care  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies met the criteria for evaluation of etanercept to supportive care. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013130-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cyclosporin compared to no cyclosporin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclosporin compared to no cyclosporin for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: cyclosporin and supportive care </p> <p><b>Comparison</b>: supportive care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cyclosporin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished prospective data for 22 participants were obtained from 1 cohort study, <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, for the comparison of cyclosporin versus other treatments (IVIG n = 4, corticosteroids n = 1, or no specified treatment n = 1). 4 participants died (1 on cyclosporin and 3 on IVIG) (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). Retrospective data as reported in the published paper are not included here.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013130-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Intravenous immunoglobulin (IVIG) compared to corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) compared to corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: IVIG </p> <p><b>Comparison</b>: corticosteroids </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies comparing IVIG to corticosteroids.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of sta</b>y ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013130-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Etanercept compared to corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital, serving as a regional referral centre for SJS/TEN cases </p> <p><b>Intervention</b>: etanercept and supportive care </p> <p><b>Comparison</b>: corticosteroids and supportive care (specifics of supportive care not identified by study) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/>(26 to 265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> </p> <p>(0.16 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported (see comments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported that 5/48 participants in the etanercept group had serious adverse events (sepsis, respiratory failure, and bipolar disorder) and 9/43 in the corticosteroids group (sepsis, respiratory failure, upper gastrointestinal haemorrhage, stridor and vocal cord palsy) (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). It is unclear from the trial report if any of these adverse events led to discontinuation of treatment or if they were attributed to systemic therapy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision, as the confidence interval is wide and includes benefits and harms, and results were from one small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013130-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Cyclosporin compared to corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclosporin compared to corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: cyclosporin </p> <p><b>Comparison</b>: corticosteroids </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cyclosporin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished prospective data for 22 participants were obtained from 1 cohort study, <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, for the comparison of cyclosporin versus other treatments (IVIG n = 4, corticosteroids n = 1, or no specified treatment n = 1). 4 participants died (1 on cyclosporin and 3 on IVIG) (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). See <a href="./full#CD013130-tbl-0009">summary of findings Table 9</a> for additional details.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013130-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Etanercept compared to intravenous immunoglobulin (IVIG)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to intravenous immunoglobulin (IVIG) for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: no studies found </p> <p><b>Intervention</b>: etanercept </p> <p><b>Comparison</b>: IVIG </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies for the comparison of etanercept to IVIG.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013130-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Cyclosporin compared to intravenous immunoglobulin (IVIG)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclosporin compared to intravenous immunoglobulin (IVIG) for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: cyclosporin  </p> <p><b>Comparison</b>: IVIG  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with other treatments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cyclosporin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality </b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(10 to 468) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.13</b> </p> <p>(0.02 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1 observational study) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished prospective data for 22 participants were obtained from 1 cohort study, <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, for the comparison of cyclosporin versus other treatments (IVIG n = 4, corticosteroids n = 1, or no specified treatment n = 1). 4 participants died (1 on cyclosporin and 3 on IVIG) (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). Retrospective data as reported in the published paper are not included here.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete re‐epithelialisation was reported only for participants treated with cyclosporin but not for other interventions. No comparison between therapies was possible. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of bias from potential confounding effects and selection bias.<br/><sup>b</sup>Downgraded one level due to imprecision, as these results were from one small study.  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013130-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Etanercept compared to cyclosporin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to cyclosporin for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: no studies found </p> <p><b>Intervention</b>: etanercept </p> <p><b>Comparison</b>: cyclosporin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cyclosporin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies for the comparison of etanercept to cyclosporin.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013130-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013130-sec-0009"></div> <p>A glossary of technical terms is provided in <a href="#CD013130-tbl-0011">Table 1</a>. </p> <div class="table" id="CD013130-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>programmed cell death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epidermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>top‐most layer of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>external to the body</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fas‐mediated apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fas‐ligand belongs to a group of proteins known as tumour necrosis factor (TNF) transmembrane proteins, which are molecules present on the surfaces of skin cells. These proteins bind (connect) with receptors, which causes the skin cells to apoptose (die). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>intravenous immunoglobulin; a medical therapy that consists of concentrated antibodies extracted from the blood of healthy donors </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mucous membrane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>skin that lines internal body cavities such as the oral cavity and the vagina</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tissue death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NF‐kB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nuclear factor kappa‐light chain enhancer of activated B cells (NF‐kB) is a protein that influences DNA transcription, thereby regulating cellular responses to various stimuli. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathogenesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the mechanism (process) of a disease</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐epithelialisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the process of skin re‐growing its outermost layer (epidermis)</p> </td> </tr> </tbody> </table> </div> <section id="CD013130-sec-0010"> <h3 class="title" id="CD013130-sec-0010">Description of the condition</h3> <p>Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare severe skin reactions most commonly triggered by medications. These three entities represent a spectrum of disease, with SJS the least and TEN the most severe, and the severity of SJS/TEN overlap syndrome in between. This spectrum of disease will be collectively referred to as SJS/TEN. The annual incidence of SJS and TEN in the general population is estimated to be 1 to 6 and 0.4 to 1.2 per million people, respectively (<a href="./references#CD013130-bbs2-0132" title="YangMS , LeeJY , KimJ , KimGW , KimBK , KimJY , et al.Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a nationwide population-based study using national health insurance database in Korea. PLOS ONE2016;11(11):e0165933. [PMID: 27835661]">Yang 2016</a>). The condition is a potentially fatal dermatological emergency, with mortality between 1% to 5% for SJS, and 25% to 40% for TEN (<a href="./references#CD013130-bbs2-0101" title="PatelTK , BarvaliyaMJ , SharmaD , TripathiC .A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian Journal of Dermatology, Venereology and Leprology2013;79(3):389-98. [PMID: 23619444]">Patel 2013</a>). </p> <p>Over 200 drugs have been associated with SJS/TEN, most frequently antibiotics, allopurinol, non‐steroidal anti‐inflammatory drugs, and anticonvulsants. The risk of SJS/TEN is greatest within weeks of the start of therapy (<a href="./references#CD013130-bbs2-0112" title="RoujeauJC , KellyJP , NaldiL , RzanyB , SternRS , AndersonT , et al.Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New England Journal of Medicine1995;333(24):1600-7. [PMID: 7477195]">Roujeau 1995</a>). Risk factors include immunocompromised status, concomitant radiotherapy with anticonvulsant use, and a slow acetylator genotype (associated with slow drug metabolism) (<a href="./references#CD013130-bbs2-0070" title="DietrichA , KawakuboY , RzanyB , MockenhauptM , SimonJC , SchöpfE .Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Experimental Dermatology1995;4(5):313-6. [PMID: 8589923]">Dietrich 1995</a>). Certain human leucocyte antigen (HLA) alleles are associated with the development of SJS/TEN, including HLA‐B*15:02 in Asians and East Indians taking carbamazepine; HLA‐B*15:02 in Han Chinese taking carbamazepine, lamotrigine, or phenytoin; HLA‐B*58‐01 in Han Chinese taking allopurinol; and HLA‐A*31‐01 in Europeans taking carbamazepine (<a href="./references#CD013130-bbs2-0065" title="CheungYK , ChengSH , ChanEJ , LoSV , NgMH , KwanP .HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia2013;54(7):1307-14. [PMID: 23692434]">Cheung 2013</a>; <a href="./references#CD013130-bbs2-0066" title="ChungWH , HungSI , HongHS , HsihMS , YangLC , HoHC , et al.Medical genetics: a marker for Stevens-Johnson syndrome. Nature2004;428(6982):486. [PMID: 15057820]">Chung 2004</a>; <a href="./references#CD013130-bbs2-0085" title="HsuDY , BrievaJ , SilverbergNB , SilverbergJI .Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. Journal of Investigative Dermatology2016;136(7):1387-97. [PMID: 27039263]">Hsu 2016</a>; <a href="./references#CD013130-bbs2-0086" title="HungSI , ChungWH , LiouLB , ChuCC , LinM , HuangHP , et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America2005;102(11):4134-9. [PMID: 15743917]">Hung 2005</a>; <a href="./references#CD013130-bbs2-0095" title="McCormackM , AlfirevicA , BourgeoisS , FarrellJJ , KasperavičiūtėD , CarringtonM , et al.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New England Journal of Medicine2011;364(12):1134-43. [PMID: 21428769]">McCormack 2011</a>). Screening programmes in Asia have resulted from these discoveries; however, despite the knowledge of these risk factors, the pathogenesis of SJS/TEN is not entirely understood. </p> <p>It is hypothesised that SJS/TEN may be due to an immune response to an antigenic complex between the culprit drug and host tissue HLAs in predisposed individuals, whereby T lymphocytes, natural killer cells, and natural killer T cells secrete granulysin and Fas‐ligand. This immune response induces apoptosis upon binding to the Fas‐ligand death receptor on keratinocytes (<a href="#CD013130-fig-0001">Figure 1</a>) (<a href="./references#CD013130-bbs2-0098" title="NickoloffBJ .Saving the skin from drug-induced detachment. Nature Medicine2008;14(12):1311-3. [PMID: 19057552]">Nickoloff 2008</a>). </p> <div class="figure" id="CD013130-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Proposed pathogenesis of SJS/TEN." data-id="CD013130-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proposed pathogenesis of SJS/TEN.</p> </div> </div> </div> <p>This spectrum of disease is characterised by widespread epidermal necrosis, which leads to separation of the epidermis from the underlying dermis. This separation causes erythema and erosion of both cutaneous and mucous membrane skin (&lt; 10% body surface area for SJS, 10% to 30% for SJS/TEN overlap, and &gt; 30% for TEN) (<a href="./references#CD013130-bbs2-0061" title="Bastuji-GarinS , RzanyB , SternRS , ShearNH , NaldiL , RoujeauJC .Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology1993;129(1):92-6.">Bastuji‐Garin 1993</a>). Acute effects of epidermal necrosis include abnormalities in fluid and electrolyte balance, temperature regulation, and protection from infection. Significant secondary complications can be acute (sepsis, respiratory distress, hypothermia, fluid loss, electrolytic abnormalities) or chronic (ocular symblepharon, entropion, blindness, chronic pain, and genital scarring with associated urethral stenosis and phimosis) (<a href="./references#CD013130-bbs2-0109" title="RevuzJ , PensoD , RoujeauJC , GuillaumeJC , PayneCR , WechslerJ , et al.Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Archives of Dermatology1987;123(9):1160-5. [PMID: 3632000]">Revuz 1987</a>), and include mental health sequelae such as depression and anxiety (<a href="./references#CD013130-bbs2-0084" title="HoffmanM , ChanskyPB , BashyamAR , BoettlerMA , ChallaN , DominguezA , et al.Long-term physical and psychological outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatology 2021 May 5 [Epub ahead of print]. [DOI: 10.1001/jamadermatol.2021.1136] [PMID: 33950191]">Hoffman 2021</a>). </p> </section> <section id="CD013130-sec-0011"> <h3 class="title" id="CD013130-sec-0011">Description of the intervention</h3> <p>Limited evidence is available to guide the treatment of SJS/TEN, thus there is wide variability in dosage, duration, and treatment regimen, with no international standard dosing for systemic therapies. In addition to tertiary‐level supportive care, various systemic therapies have been used, including glucocorticoids, intravenous immunoglobulin (IVIG), cyclosporin (calcineurin inhibitor), N‐acetylcysteine, thalidomide (immunomodulator), infliximab or etanercept (tumour necrosis factor‐alpha (TNF‐alpha) inhibitors), and plasmapheresis. Through various mechanisms (see <a href="#CD013130-sec-0012">How the intervention might work</a>), these systemic therapies potentially halt the progression and lessen the severity of SJS/TEN. Supportive care measures include wound care; eye, mouth, and genital skin care; nutrition; fluid replacement; and care provided at a tertiary care centre. This review examines systemic medical interventions only. </p> <p>Few randomised controlled trials (RCTs) have examined systemic therapy for SJS/TEN. A study that compared thalidomide versus supportive care in patients with TEN was stopped early owing to higher‐than‐predicted mortality (10 of 12 participants in the thalidomide group versus 3 of 10 in the placebo group) (<a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a>). This is the only study to be included in a prior Cochrane Review of systemic therapies specifically for TEN, which was published in 2002 (<a href="./references#CD013130-bbs2-0137" title="MajumdarS , MockenhauptM , RoujeauJC , TownshendAP .Interventions for toxic epidermal necrolysis. Cochrane Database of Systematic Reviews2002, Issue 4. Art. No: CD001435. [DOI: 10.1002/14651858.CD001435]">Majumdar 2002</a>). The authors of that review concluded that there was no reliable evidence to support treatment decisions for TEN. More recently, an RCT of 96 participants with SJS/TEN reported less‐than‐predicted mortality for patients treated with etanercept (8.3% observed versus 17.7% predicted deaths) based on severity of illness score or SCORe of Toxic Epidermal Necrolysis (SCORTEN) criteria; this mortality was less than that predicted for patients treated with corticosteroids (16.3%), and neither result was statistically significant (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>).  </p> <p>Retrospective cohorts from the EuroSCAR and RegiSCAR trials provide robust data on systemic therapies for SJS/TEN, with close to 1000 participants from these studies combined. The studies have examined survival benefit in patients treated with a variety of regimens including corticosteroids, supportive care, IVIG, and cyclosporin (<a href="./references#CD013130-bbs2-0063" title="CampioneE , MarulliGC , CarrozzoAM , ChimentiMS , CostanzoA , BianchiL .High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Dermato-Venereologica2003;83(6):430-2. [PMID: 14690337]">Campione 2003</a>; <a href="./references#CD013130-bbs2-0076" title="FayeO , RoujeauJC .Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs2005;65(15):2085-90. [PMID: 16225365]">Faye 2005</a>; <a href="./references#CD013130-bbs2-0104" title="PrinsC , KerdelFA , PadillaRS , HunzikerT , ChimentiS , ViardI , et al.Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Archives of Dermatology2003;139(1):26-32. [PMID: 12533160]">Prins 2003</a>; <a href="./references#CD013130-bbs2-0117" title="SekulaP , DunantA , MockenhauptM , NaldiL , Bouwes BavinckJN , HalevyS , et al.Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Investigative Dermatology2013;133(5):1197-204. [PMID: 23389396]">Sekula 2013</a>; <a href="./references#CD013130-bbs2-0119" title="StellaM , CassanoP , BolleroD , ClementeA , GiorioG .Toxic epidermal necrolysis treated with intravenous high dose immunoglobulins: our experience. Dermatology2001;203(1):45-9. [PMID: 11549799]">Stella 2001</a>; <a href="./references#CD013130-bbs2-0124" title="TrentJT , KirsnerRS , RomanelliP , KerdelFA .Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Archives of Dermatology2008;139(1):39-43. [PMID: 12533162]">Trent 2008</a>; <a href="./references#CD013130-bbs2-0125" title="Tristani-FirouziP , PetersenMJ , SaffleJR , MorrisSE , ZoneJJ .Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. Journal of the American Academy of Dermatology2002;47(4):548-52. [PMID: 12271299]">Tristani‐Firouzi 2002</a>; <a href="./references#CD013130-bbs2-0128" title="ViardI , WehrliP , BullaniR , SchneiderP , HollerN , SalomonD , et al.Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science1998;282(5388):490-3. [PMID: 9774279]">Viard 1998</a>). Other case series and small cohorts and a phase 2 non‐randomised trial assessed the effect of cyclosporin in halting the progression of SJS/TEN (<a href="./references#CD013130-bbs2-0059" title="ArévaloJM , LorenteJA , González-HerradaC , Jiménez- ReyesJ .Treatment of toxic epidermal necrolysis with cyclosporin A. Journal of Trauma2000;48(3):473-8. [PMID: 10744287]">Arevalo 2000</a>; <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>; <a href="./references#CD013130-bbs2-0087" title="JarrettP , RademakerM , HavillJ , PullonH .Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clinical and Experimental Dermatology1997;22(3):146-7. [PMID: 9425696]">Jarrett 1997</a>; <a href="./references#CD013130-bbs2-0088" title="KirchhofMG , MiliszewskiMA , SikoraS , PappA , DutzJP .Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. Journal of the American Academy of Dermatology2014;71(5):941-7. [PMID: 25087214]">Kirchhof 2014</a>; <a href="./references#CD013130-bbs2-0103" title="PoizeauF , GaudinO , Le CleachL , DuongTA , HuaC , HotzC , et al.Ciclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients - exposed/unexposed and propensity-score matched analyses. Journal of Investigative Dermatology2018;138(6):1293-300. [PMID: 29369774]">Poizeau 2018</a>; <a href="./references#CD013130-bbs2-0105" title="RaiR , SrinivasCR .Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis. Indian Journal of Dermatology, Venereology and Leprology2008;74(3):263-5. [PMID: 18583801]">Rai 2008</a>; <a href="./references#CD013130-bbs2-0106" title="ReeseD , HenningJS , RockersK , LaddD , GilsonR .Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis2011;87(1):24-9. [PMID: 21323097]">Reese 2011</a>; <a href="./references#CD013130-bbs2-0110" title="RobakE , RobakT , Góra-TyborJ , ChojnowskiK , StrzeleckaB , WaszczykowskaE , et al.Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. Journal of Medicine2001;32(1-2):31-9. [PMID: 11321886]">Robak 2001</a>; <a href="./references#CD013130-bbs2-0123" title="SullivanJR , WatsonA .Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australian Journal of Dermatology1996;37(4):208-12. [PMID: 8961591]">Sullivan 1996</a>; <a href="./references#CD013130-bbs2-0133" title="ZakiI , PatelS , ReedR , DalzielKL .Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. British Journal of Dermatology1995;133(2):337-8. [PMID: 7547417]">Zaki 1995</a>). </p> <p>Tumour necrosis factor inhibitors (anti‐TNF agents) are the newest agents under study for use in SJS/TEN. Several reports have shown that infliximab given as a single infusion of 5 mg/kg halts skin sloughing and induces rapid re‐epithelialisation (no erosions or active lesions) of denuded skin (<a href="./references#CD013130-bbs2-0102" title="PatmanidisK , SidirasA , DolianitisK , SimelidisD , SolomonidisC , GaitanisG , et al.Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Reports in Dermatological Medicine2012;2012:915314. [PMID: 23259092]">Patmanidis 2012</a>; <a href="./references#CD013130-bbs2-0116" title="Scott-LangV , TidmanM , McKayD .Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatric Dermatology2014;31(4):532-4. [PMID: 23072342]">Scott‐Lang 2014</a>; <a href="./references#CD013130-bbs2-0130" title="WojtkiewiczA , WysockiM , FortunaJ , ChrupekM , MatczukM , KoltanA , et al.Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Dermato-Venereologica2008;88(4):420-1. [PMID: 18709327]">Wojtkiewicz 2008</a>; <a href="./references#CD013130-bbs2-0134" title="Zárate-CorreaLC , Carrillo-GómezDC , Ramírez-EscobarAF , Serrano-ReyesC .Toxic epidermal necrolysis successfully treated with infliximab. Journal of Investigational Allergology &amp; Clinical Immunology2013;23(1):61-3. [PMID: 23653980]">Zarate‐Correa 2013</a>). A few case series have described similar results with a single 50 mg subcutaneous injection of etanercept (<a href="./references#CD013130-bbs2-0075" title="FamularoG , DiDonaB , CanzonaF , GirardelliCR , CrucianiG .Etanercept for toxic epidermal necrolysis. Annals of Pharmacotherapy2007;41(6):1083-4. [PMID: 17456541]">Famularo 2007</a>; <a href="./references#CD013130-bbs2-0078" title="GubinelliE , CanzonaF , TonanziT , RaskovicD , DidonaB .Toxic epidermal necrolysis successfully treated with etanercept. Journal of Dermatology2009;36(3):150-3. [PMID: 19335689]">Gubinelli 2009</a>; <a href="./references#CD013130-bbs2-0100" title="ParadisiA , AbeniD , BergamoF , RicciF , DidonaD , DidonaB .Etanercept therapy for toxic epidermal necrolysis. Journal of the American Academy of Dermatology2014;71(2):278-83. [PMID: 24928706]">Paradisi 2014</a>). The true benefit of anti‐TNF agents in SJS/TEN is difficult to ascertain because published studies on this topic are few. </p> <p>In addition to mortality, time to complete re‐epithelialisation is an important and validated endpoint. Several studies have also attempted to evaluate re‐epithelialisation when treated with supportive care, corticosteroids, IVIG, cyclosporin, or etanercept (<a href="./references#CD013130-bbs2-0075" title="FamularoG , DiDonaB , CanzonaF , GirardelliCR , CrucianiG .Etanercept for toxic epidermal necrolysis. Annals of Pharmacotherapy2007;41(6):1083-4. [PMID: 17456541]">Famularo 2007</a>; <a href="./references#CD013130-bbs2-0091" title="LalosevicJ , NikolicM , Gajic-VeljicM , SkiljevicD , MedenicaL .Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. International Journal of Dermatology2015;54(8):978-84. [PMID: 25385069]">Lalosevic 2015</a>; <a href="./references#CD013130-bbs2-0097" title="NapolitanoM , GiampetruzziAR , DidonaD , PapiM , DidonaB .Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. Journal of the American Academy of Dermatology2013;69(6):E303-5. [PMID: 24238188]">Napolitano 2013</a>; <a href="./references#CD013130-bbs2-0100" title="ParadisiA , AbeniD , BergamoF , RicciF , DidonaD , DidonaB .Etanercept therapy for toxic epidermal necrolysis. Journal of the American Academy of Dermatology2014;71(2):278-83. [PMID: 24928706]">Paradisi 2014</a>; <a href="./references#CD013130-bbs2-0118" title="SinghGK , ChatterjeeM , VermaR .Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian Journal of Dermatology, Venereology and Leprology2013;79(5):686-92. [PMID: 23974585]">Singh 2013</a>; <a href="./references#CD013130-bbs2-0127" title="Valeyrie-AllanoreL , WolkensteinP , BrochardL , OrtonneN , MaîtreB , RevuzJ , et al.Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology2010;163(4):847-53. [PMID: 20500799]">Valeyrie‐Allanore 2010</a>; <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). </p> </section> <section id="CD013130-sec-0012"> <h3 class="title" id="CD013130-sec-0012">How the intervention might work</h3> <p>The interventions described above involve several potential mechanisms. As the SJS/TEN disease spectrum is believed to be an immune response to an exogenous agent, initial studies investigated the use of steroids to reduce this response (<a href="./references#CD013130-bbs2-0131" title="YamaneY , MatsukuraS , WatanabeY , YamaguchiY , NakamuraK , KambaraT , et al.Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients. Allergy International2016;65(1):74-81. [PMID: 26666483]">Yamane 2016</a>). Dysregulation of Fas‐mediated apoptosis has also been implicated in SJS/TEN, and IVIG is thought to act through autoantibodies against Fas (<a href="./references#CD013130-bbs2-0111" title="RomanelliP , SchlamE , GreenJB , TrentJT , RicottiC , ElgartGW , et al.Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin. Giornale Italiano di Dermatologia e Venereologia2008;143(4):229-33. [PMID: 18833079]">Romanelli 2008</a>). The ultimate target of immunomodulating or suppressive therapies is to reduce the action of activated T‐lymphocytes and cytokines whilst reducing granulysin at the cellular level to arrest cytotoxicity and apoptosis of the skin and mucosal surfaces. This is the case of TNF‐alpha inhibitors such as etanercept or infliximab (<a href="./references#CD013130-bbs2-0064" title="ChaveTA , MortimerNJ , SladdenMJ , HallAP , HutchinsonPE .Toxic epidermal necrolysis: current evidence, practical management and future directions. British Journal of Dermatology2005;153(2):241-53. [PMID: 16086734]">Chave 2005</a>), or thalidomide (<a href="./references#CD013130-bbs2-0089" title="KlausnerJD , FreedmanVH , Kaplan G .Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clinical Immunology and Immunopathology1996;81:219-23.">Klausner 1996</a>), although thalidomide is a weak inhibitor of TNF alpha. TNF‐alpha inhibitors have also been shown to have an effect on increasing the Treg population to downregulate T‐cells and reduce granulysin, which is the ultimate effector of SJS‐TEN (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). Cyclosporin is supposed to act through inhibiting interleukin‐15 (IL‐15) and IL‐17, which are the main drivers of TNF‐alpha (<a href="./references#CD013130-bbs2-0122" title="Su S-C, MockenhauptM , WolkensteinP , DunantA , Le GouvelloS , Chen C-B, et al.Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. Journal of Investigative Dermatology2017;137(5):1065-73.">Su 2017</a>). Cyclophosphamide leads as well to cell apoptosis through DNA alkylation and T‐cell inhibition. Other mechanisms of action include the removal of pathogenic particles from blood (like plasmapheresis), as investigated by <a href="./references#CD013130-bbs2-0131" title="YamaneY , MatsukuraS , WatanabeY , YamaguchiY , NakamuraK , KambaraT , et al.Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients. Allergy International2016;65(1):74-81. [PMID: 26666483]">Yamane 2016</a>, or haemoperfusion (<a href="./references#CD013130-bbs2-0079" title="HallAG , TilbyMJ .Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Reviews1992;6(3):163-73.">Hall 1992</a>), enhanced bioregeneration of the skin tissues through accelerated re‐epithelialisation with granulocyte colony‐stimulating factor (<a href="./references#CD013130-bbs2-0069" title="deSica-ChapmanA , WilliamsG , SoniN , BunkerCB .Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea &amp; Westminster TEN management protocol [corrected]. British Journal of Dermatology2010;162(4):860-5.">de Sica‐Chapman 2010</a>), and downregulation of NF‐kB (cyclosporin and N‐acetylcysteine), as studied by <a href="./references#CD013130-bbs2-0090" title="KohanimS , PaliouraS , SaeedHN , AkpekEK , AmescuaG , BasuS , et al.Stevens-Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. I. Systemic disease. Ocular Surface2016;14(1):2-19. [PMID: 26549248]">Kohanim 2016</a> and <a href="./references#CD013130-bbs2-0080" title="HasanMJ , RabbaniR .Intravenous N-acetylcysteine in severe cutaneous drug reaction treatment: a case series. SAGE Open Medical Case Reports2020;8:2050313X2093470.">Hasan 2020</a>. </p> </section> <section id="CD013130-sec-0013"> <h3 class="title" id="CD013130-sec-0013">Why it is important to do this review</h3> <p>Given the rarity of this disease, evidence of treatment efficacy is limited, and most has been derived from retrospective, uncontrolled studies including few participants. Most patients thus continue to be treated according to institutional experience. In a practice survey of 147 North American centres treating patients with SJS/TEN (130 burn centres and 17 academic dermatology centres), only 54% of physicians reported that they followed treatment guidelines or an institutional standard of care for SJS/TEN, and only a minority of these physicians used professionally published guidelines (<a href="./references#CD013130-bbs2-0072" title="Dodiuk-GadRP , OlteanuC , JeschkeMG , CartottoR , FishJ , ShearNH .Treatment of toxic epidermal necrolysis in North America. Journal of the American Academy of Dermatology2015;73(5):876-7. [PMID: 26475545]">Dodiuk‐Gad 2015</a>). IVIG was the first choice at more than 80% of sites, followed by systemic corticosteroids, cyclosporin, anti‐TNF medications, and supportive care alone (provided at 14% of centres). This pattern of practice is markedly different from published expert opinions (iSCAR meeting 2013, as reported by <a href="./references#CD013130-bbs2-0072" title="Dodiuk-GadRP , OlteanuC , JeschkeMG , CartottoR , FishJ , ShearNH .Treatment of toxic epidermal necrolysis in North America. Journal of the American Academy of Dermatology2015;73(5):876-7. [PMID: 26475545]">Dodiuk‐Gad 2015</a>, and a multidisciplinary expert group meeting in 2017, as reported by <a href="./references#CD013130-bbs2-0129" title="WhiteKD , AbeR , Ardern-JonesM , BeachkofskyT , BouchardC , CarletonB , et al.SJS/TEN 2017: Building multidisciplinary networks to drive science and translation. Journal of Allergy and Clinical Immunology Practice2018;6(1):38-69.">White 2018</a>). </p> <p>A recent meta‐analysis of 96 studies including 3248 participants showed survival benefit for cyclosporin and glucocorticoids but not for supportive care alone, IVIG, plasmapheresis, thalidomide, cyclophosphamide, anti‐TNF agents, haemoperfusion, or granulocyte colony‐stimulating factor (<a href="./references#CD013130-bbs2-0135" title="ZimmermannS , SekulaP , VenhoffM , MotschallE , KnausJ , SchumacherM , et al.Systemic immunomodulating therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a systematic review and meta-analysis. JAMA Dermatology2017;153(6):514-22.">Zimmermann 2017</a>). This is the only meta‐analysis to comprehensively evaluate treatments for SJS/TEN. Proposed strengths of our own review will include use of Cochrane methods, which involve rigorous quality assessment of included studies and inclusion of only prospective studies (cohort and prospective patient registry studies) to ensure the highest quality of included data. </p> <p>The topic of this review was covered in part by the Cochrane Review titled 'Interventions for toxic epidermal necrolysis' (<a href="./references#CD013130-bbs2-0137" title="MajumdarS , MockenhauptM , RoujeauJC , TownshendAP .Interventions for toxic epidermal necrolysis. Cochrane Database of Systematic Reviews2002, Issue 4. Art. No: CD001435. [DOI: 10.1002/14651858.CD001435]">Majumdar 2002</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013130-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013130-sec-0014"></div> <p>To assess the effects of all systemic therapies (medicines delivered orally, intramuscularly, or intravenously) for the treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013130-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013130-sec-0015"></div> <section id="CD013130-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013130-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs and prospective comparative studies only, due to a lack of validated tools for assessing risk of bias in uncontrolled studies. We defined 'prospective' as studies that collected data from the point of patient inclusion in the study, and 'comparative' as when studies had a control group or a second arm to compare with. We excluded cross‐over trials due to the inability to get an adequate wash‐out period for patients with this condition. There were no restrictions on language or publication status (published, unpublished, in press, or in progress). </p> </section> <section id="CD013130-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants of any age with a clinical diagnosis of SJS, TEN, or SJS/TEN overlap syndrome. Given the rarity of SJS/TEN and the limited number of studies to date, we also included studies in which participants with SJS/TEN represented a subset of the overall study population, but only included data for the SJS/TEN patients specifically. We classified SJS/TEN as per published criteria (<a href="./references#CD013130-bbs2-0061" title="Bastuji-GarinS , RzanyB , SternRS , ShearNH , NaldiL , RoujeauJC .Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology1993;129(1):92-6.">Bastuji‐Garin 1993</a>), but included all studies reporting a clinical diagnosis of SJS/TEN. </p> </section> <section id="CD013130-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included all systemic therapies studied to date, including corticosteroids, IVIG, cyclosporin, N‐acetylcysteine, thalidomide, infliximab, plasmapheresis, and etanercept. We included comparisons between each of the therapies outlined when data were available (28 possible comparisons). In addition, we included comparisons of some therapies versus placebo (supportive care alone versus the intervention with supportive care) when such data were available. </p> </section> <section id="CD013130-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We considered the following primary and secondary outcome measures, where data were available.  </p> <section id="CD013130-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013130-list-0001"> <li> <p>SJS/TEN‐specific mortality: mortality within one month of onset of SJS/TEN that is not clearly attributed to another cause </p> </li> <li> <p>Adverse effects leading to discontinuation of SJS/TEN therapy: events that occur within one month following administration of therapy that are listed as potential adverse effects in the product monograph and lead to discontinuation of therapy </p> </li> </ul> </p> </section> <section id="CD013130-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013130-list-0002"> <li> <p>Time to complete re‐epithelialisation: number of days to full skin healing</p> </li> <li> <p>Intensive care unit (ICU) length of stay: time during which participant is admitted to ICU ward, as reported when available </p> </li> <li> <p>Total hospital length of stay: time during which participant is admitted to hospital, as reported when available </p> </li> <li> <p>Illness sequelae (chronic mucocutaneous morbidity): sequelae that clinically makes sense as possible outcomes of SJS/TEN including cutaneous (scarring, dyspigmentation, loss of nails), ocular (cicatricial conjunctivitis, corneal perforation/ ulceration/epithelial defects, entropion/ectropion, chronic dry eye, symblepharon, blindness), gastrointestinal (ulceration, perforation, strictures), genitourinary (vaginal stenosis, phimosis, urethral strictures), and respiratory events (bronchiolitis, bronchiectasis, obstructive lung disease), and chronic pain </p> </li> <li> <p>Other adverse effects attributed to systemic therapy: events that occur within one month following administration of therapy that are listed as potential adverse effects in the product monograph and do not lead to discontinuation of therapy </p> </li> </ul> </p> <p>We included these outcomes because literature reviews and clinical experience indicate that they are important considerations for patients with SJS/TEN. Besides reducing mortality, the purpose of treating SJS/TEN is to increase the speed of skin healing to minimise the potential for illness sequelae. Length of stay in hospital, including the ICU, is an important determinant of healthcare costs. Furthermore, minimising time spent in hospital reduces the risk of hospital‐acquired illness among these patients. We collected data on these measures at any and all outcome time points. </p> <section id="CD013130-sec-0023"> <h6 class="title">Prespecified confounders and co‐interventions for non‐randomised studies</h6> <p>Confounders identified a priori include disease duration (first day of symptoms to initiation of treatment), disease severity (as determined by SCORTEN; <a href="./references#CD013130-bbs2-0062" title="Bastuji-GarinS , FouchardN , BertocchiM , RoujeauJC , RevuzJ , WolkensteinP .SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. Journal of Investigative Dermatology2000;115(2):149-53. [PMID: 10951229]">Bastuji‐Garin 2000</a>), use of diagnostic criteria (as published in <a href="#CD013130-tbl-0012">Table 2</a>; <a href="./references#CD013130-bbs2-0061" title="Bastuji-GarinS , RzanyB , SternRS , ShearNH , NaldiL , RoujeauJC .Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology1993;129(1):92-6.">Bastuji‐Garin 1993</a>), baseline comorbidities, age distribution, duration of follow‐up, and the use of co‐interventions (i.e. supportive care, other systemic medical treatments). These variables may confound the relationship between SJS/TEN treatment and disease‐specific mortality, as they are related to these variables and, when not adjusted for, may impact the measure of treatment effect. For example, if treatment X is used only for patients who have better disease prognosis (present to hospital early in their disease, have less severe disease, are younger, have fewer baseline comorbidities), the effect of treatment X on reducing mortality may be overestimated. Similarly, studies that do not use diagnostic criteria may include other diseases that are less severe than SJS/TEN (such as erythema multiforme), which may lead to the overestimation of treatment effects. Duration of follow‐up is also important, as studies with shorter follow‐up (i.e. less than one month) may underestimate SJS/TEN mortality, which again would lead to overestimation of the treatment effect. We included non‐randomised studies in the analysis that did not adjust for these prespecified confounders, and assessed the possible impact of these confounders using the Risk of Bias In Non‐randomised Studies – of Interventions (ROBINS‐I) tool (<a href="./references#CD013130-bbs2-0120" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al.ROBINS-1: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [PMID: 27733354]">Sterne 2016</a>), as detailed below.  </p> <div class="table" id="CD013130-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Diagnostic criteria for Stevens‐Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as proposed by Bastuji and colleagues (1993)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Classification</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Types of lesions*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Distribution</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Percentage of body surface area detached/detachable</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bullous erythema multiforme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Typical or atypical raised targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SJS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spots ± flat atypical targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overlap SJS/TEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spots ± flat atypical targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 10 to 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TEN with spots</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spots ± flat atypical targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TEN without spots</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No spots or targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 10</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Typical targets: lesions &lt; 3 cm with well‐defined borders and regular round shape with 3 separate zones of colour; atypical targets: flat or palpable lesions with 2 zones of colour and poorly defined borders. </p> </div> </div> </section> </section> </section> </section> <section id="CD013130-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs and prospective observational comparative studies regardless of language or publication status (published, unpublished, in press, or in progress).  </p> <section id="CD013130-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Skin Information Specialist (Liz Doney) searched the following databases up to 10 March 2021 using strategies based on the draft strategy for MEDLINE in our published protocol (<a href="./references#CD013130-bbs2-0136" title="LangleyA , WorleyB , Pardo PardoJ , BeeckerJ , RamsayT , SaavedraA , et al.Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database of Systematic Reviews2018, Issue 9. Art. No: CD013130. [DOI: 10.1002/14651858.CD013130]">Langley 2018</a>): </p> <p> <ul id="CD013130-list-0003"> <li> <p>the Cochrane Skin Specialised Register using the search strategy in <a href="./appendices#CD013130-sec-0098">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 2021, Issue 3, in the Cochrane Library using the strategy in <a href="./appendices#CD013130-sec-0099">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD013130-sec-0100">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD013130-sec-0101">Appendix 4</a>. </p> </li> </ul> </p> <section id="CD013130-sec-0026"> <h5 class="title">Trial registers</h5> <p>One of two review authors (AL or BO) searched the following trial registers using the search terms: Stevens‐Johnson syndrome, toxic epidermal necrolysis, SJS, and Lyell’s syndrome or Lyell’s disease, up to 21 May 2020. </p> <p> <ul id="CD013130-list-0004"> <li> <p>ISRCTN register (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>) </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>) </p> </li> </ul> </p> </section> </section> <section id="CD013130-sec-0027"> <h4 class="title">Searching other resources</h4> <section id="CD013130-sec-0028"> <h5 class="title">Reference lists</h5> <p>One of two review authors (AL or BO) checked the reference lists of all included studies and key review articles for additional references to relevant trials. </p> </section> <section id="CD013130-sec-0029"> <h5 class="title">Relevant organisations</h5> <p>One of three review authors (AL, BO, or FS) searched up to March 2021 for clinical trials records on the following drug manufacturers’ websites using the search terms ‘Steven Johnson syndrome’ and ‘toxic epidermal necrolysis’: </p> <p> <ul id="CD013130-list-0005"> <li> <p>Intravenous immunoglobulins: Grifols (<a href="https://www.grifols.com/en/home" target="_blank">www.grifols.com</a>); </p> </li> <li> <p>Cyclosporin: Novartis (<a href="https://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov" target="_blank">www.novartisclinicaltrials.com</a>); </p> </li> <li> <p>N‐acetylcysteine: Pfizer (<a href="https://www.pfizer.com/science/clinical-trials" target="_blank">www.pfizer.com/science/clinical-trials</a>); </p> </li> <li> <p>Thalidomide: Bristol Myers‐Squibb (<a href="https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html" target="_blank">www.bms.com/researchers-and-partners/clinical-trials-and-research.html</a>); </p> </li> <li> <p>Infliximab: Janssen (<a href="https://globaltrialfinder.janssen.com/" target="_blank">www.globaltrialfinder.janssen.com</a>); </p> </li> <li> <p>Etanercept: Amgen (<a href="https://www.amgen.com/science/clinical-trials" target="_blank">www.amgen.com/science/clinical-trials</a>). </p> </li> </ul> </p> </section> <section id="CD013130-sec-0030"> <h5 class="title">Errata or retractions</h5> <p>One of two review authors (AL or BO) searched for errata or retractions of the included studies up to 16 February 2021 using MEDLINE and the <a href="http://retractiondatabase.org/RetractionSearch.aspx?" target="_blank">Retraction Watch</a> database. </p> </section> <section id="CD013130-sec-0031"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of SJS, TEN, and SJS/TEN overlap syndrome.  We considered adverse effects described in the included studies only. </p> </section> </section> </section> <section id="CD013130-sec-0032"> <h3 class="title" id="CD013130-sec-0032">Data collection and analysis</h3> <section id="CD013130-sec-0033"> <h4 class="title">Selection of studies</h4> <p>All search results were merged into Covidence reference management software and duplicates removed (<a href="./references#CD013130-bbs2-0067" title="Covidence.Version accessed 5 June 2018. Melbourne, Australia: Veritas Health Innovation, 2018. Available at covidence.org.">Covidence</a>). </p> <p>Two review authors (AL, AS, EM, BO, RP, or AJ) independently reviewed and selected abstracts based on relevancy to the research question. Any discrepancies were resolved by discussion or by consulting a third review author (AS, EM, BO, RP, or AJ) if required. The full texts of selected abstracts were obtained and stored in Covidence. Two review authors (AL, EM, BO, RP, or AJ) reviewed the full texts to determine if they met the inclusion criteria, with any discrepancies resolved by discussion or with input from a third review author (AS, BO, RP, or AJ) if required. When selected abstracts meeting the inclusion criteria did not have associated full‐text publications, we contacted the study authors to obtain full data. When full data were not available but abstracts still met the inclusion criteria, data from the abstracts were extracted and managed as outlined below. We created a PRISMA flow diagram (<a href="#CD013130-fig-0002">Figure 2</a>) to outline study selection, and a <a href="./references#CD013130-sec-0112" title="">Characteristics of excluded studies</a> highlighting the reasons for exclusion of the excluded studies (<a href="./references#CD013130-bbs2-0073" title="Institute of Medicine (US) Committee on Standards for Systematic Reviews of Comparative Effectiveness Research.Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist. In: EdenJ , LevitL , BergA , et al, editors(s). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press, 2011.">Eden 2011</a>). We collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. </p> <div class="figure" id="CD013130-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013130-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013130-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We extracted data for each included study into <a href="./references#CD013130-sec-0111" title="">Characteristics of included studies</a> tables. Two review authors (AL, EM, BO, RP, or AJ) independently extracted the following study characteristics from reports of the included studies following the form in <a href="#CD013130-tbl-0013">Table 3</a>. </p> <div class="table" id="CD013130-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Data collection</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study information</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Citation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to initial skin healing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Date of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total duration of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age, range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to full skin healing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details of any run‐in period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concomitant medications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hospital length of stay</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable declarations of interest of study authors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of study centres</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethnicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded medications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean intensive care unit (ICU) length of stay</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study locations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnostic criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects of treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Illness sequelae (chronic mucocutaneous morbidity)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean day of illness at which treatment was initiated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations:</b> SMR: standardised mortality ratio, a ratio of the observed number of deaths to the number of deaths expected for a standard population of known age and sex distribution. </p> </div> </div> <p> <ul id="CD013130-list-0006"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals, study dates. </p> </li> <li> <p>Participants: number of participants, mean age, age range, sex, ethnicity, disease duration, severity of condition, diagnostic criteria, baseline comorbidities, inclusion criteria, exclusion criteria. </p> </li> <li> <p>Interventions: interventions, comparisons, concomitant medications, supportive care measures, excluded medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified above (number of events and number of participants per treatment group for dichotomous outcomes, and means and standard deviations and number of participants per treatment group for continuous outcomes. Both adjusted and unadjusted measures of treatment effect were collected, as well as time points for data collection). </p> </li> <li> <p>Notes: funding for trial, notable declarations of interest of trial authors.</p> </li> </ul> </p> <p>Any disagreements were resolved by consensus or by involving a third review author if required (JPP). One review author (AL or BO) transferred extracted data into the Review Manager 5 (<a href="./references#CD013130-bbs2-0107" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>) and RevMan Web (<a href="./references#CD013130-bbs2-0108" title="Review Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). We compared each study against the PRISMA checklist for inclusion of information reported in the study protocol, when this was available. </p> </section> <section id="CD013130-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (AL, BO, AJ, and FS) independently assessed risk of bias for each study's outcome result included in the summary of findings tables. We evaluated bias in RCTs using Cochrane’s RoB 2 tool (22 August 2019 version) for effect of assignment to the intervention (<a href="./references#CD013130-bbs2-0082" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC .Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>; <a href="./references#CD013130-bbs2-0121" title="Sterne JAC,  Savović J,  Page MJ,  Elbers RG,  Blencowe NS,  Boutron I, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). We assessed risk of bias as low, high, or some concerns, for the domains described below. </p> <p> <ul id="CD013130-list-0007"> <li> <p>Domain 1: Risk of bias arising from the randomisation process</p> </li> <li> <p>Domain 2: Risk of bias due to deviations from the intended interventions</p> </li> <li> <p>Domain 3: Missing outcome data</p> </li> <li> <p>Domain 4: Risk of bias in measurement of the outcome</p> </li> <li> <p>Domain 5: Risk of bias in selection of the reported result</p> </li> </ul> </p> <p>We then determined an overall risk of bias for each result. If any domain was graded as high, the overall risk of bias for the study was considered to be high. We planned that if we identified cluster‐RCTs we would use Cochrane’s RoB 2 tool adding a domain specific for cluster‐RCTs (<a href="./references#CD013130-bbs2-0074" title="Eldridge S, CampbellMK , CampbellMJ , DrahotaAK , Giraudeau B, ReevesBC , et al.Revised Cochrane risk of bias tool for randomized trials (RoB 2). Additional considerations for cluster-randomized trials (RoB 2 CRT). www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-cluster-randomized-trials (accessed 20 January 2021).">Eldridge 2020</a>), using the signalling questions in combination with guidance on cluster‐RCTs in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013130-bbs2-0083" title="HigginsJPT , Eldridge S, LiT .Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021c</a>). </p> <p>We assessed each outcome result from non‐randomised studies for bias using the ROBINS‐I tool as developed by members of the Cochrane Non‐Randomized Studies for Interventions Methods Group (<a href="./references#CD013130-bbs2-0120" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al.ROBINS-1: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [PMID: 27733354]">Sterne 2016</a>). We evaluated the effect of assignment to the intervention. We assessed risk of bias as 'low', 'moderate', 'serious', or 'critical' for the domains described below, with an additional option of 'no information'. We then determined an overall risk of bias for each result. If any domain was graded as critical, the overall risk of bias was considered to be critical.  </p> <p> <ul id="CD013130-list-0008"> <li> <p>Bias due to confounding</p> </li> <li> <p>Bias in selection of participants into the study</p> </li> <li> <p>Bias in classification of interventions</p> </li> <li> <p>Bias due to deviations from intended interventions</p> </li> <li> <p>Bias due to missing data</p> </li> <li> <p>Bias in measurement of outcomes</p> </li> <li> <p>Bias in selection of the reported result</p> </li> </ul> </p> <p>We used the templates for the Cochrane RoB 2 and ROBINS‐I tools to assess risk of bias, available at <a href="http://www.riskofbias.info" target="_blank">www.riskofbias.info</a>. Any disagreements were resolved through consensus with the Cochrane Skin Group. We used the robvis tool to create risk of bias summary figures (<a href="./references#CD013130-bbs2-0096" title="McGuinnessLA , HigginsJPT .Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods2020;12(1):55-61. [DOI: 10.1002/jrsm.1411]">McGuinness 2020</a>). </p> </section> <section id="CD013130-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>We collected effect estimates from each study. When researchers provided both adjusted and unadjusted measures of treatment effect, we would collect both. 'Adjusted measures' refers to those produced from multi‐variate analyses that adjust for the confounding effects of covariates. Although adjusted data were preferred for the analysis, the collection of unadjusted data would have allowed us to perform a sensitivity analysis for inclusion of these data in the results. </p> <p>We analysed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). This was completed using RevMan Web (<a href="./references#CD013130-bbs2-0108" title="Review Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>).  </p> <p>We analysed continuous data as mean differences (MDs) or standardised mean differences (SMDs), depending on whether the same scale was used to measure a given outcome, and 95% CIs. We entered data presented as a scale with a consistent direction of effect across studies.  </p> <p>If in future updates different scales are used to measure the same conceptual outcome (e.g. disability), we will calculate SMDs instead with corresponding 95% CIs. We plan to convert SMDs back to MDs on a typical scale (e.g. 0 to 10 for pain) by multiplying the SMD by a typical amongst‐person standard deviation (e.g. standard deviation of the control group at baseline from the most representative trial), as per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013130-bbs2-0082" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC .Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>).  </p> <p>We intended to analyse time‐to‐event data as hazard ratios and rate data using Poisson methods (<a href="./references#CD013130-bbs2-0093" title="LawlessJF .Regression methods for Poisson process data. Journal of the American Statistical Association1986;82(399):808-15. [DOI: 10.2307/2288790]">Lawless 1986</a>); however, insufficient data precluded this analysis.  </p> <p>When pooling results, for dichotomous outcomes we planned to calculate the absolute risk difference using the risk difference statistic in Review Manager 5 (<a href="./references#CD013130-bbs2-0107" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>) or RevMan Web (<a href="./references#CD013130-bbs2-0108" title="Review Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>) and to express the result as a percentage. We also planned to calculate the relative per cent change for dichotomous data as 'Risk ratio − 1', and express this as a percentage, if possible. </p> </section> <section id="CD013130-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in each study was the individual participant, and we sought to obtain participant‐level data for all included studies. We planned to conduct a meta‐analysis only where this was meaningful, that is if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense based on heterogeneity assessment. We would analyse studies by grouping them according to study design, and provide a global estimate in the context of analysis of each study design. If data from RCT versus non‐RCT studies were sufficiently similar with minimal heterogeneity, we would cautiously consider a pooled meta‐analysis. </p> <p>We included cluster‐RCTs by accounting for within‐cluster participant correlation in the analysis (<a href="./references#CD013130-bbs2-0081" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from handbook.cochrane.org.">Higgins 2021a</a>).  We excluded cross‐over trials due to concerns with carryover effects. Within‐participant (split‐body) RCTs are not relevant to this topic, which pertains to systemic therapies only, and were therefore excluded. </p> </section> <section id="CD013130-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as abstract only, or when data were not available for all participants). When this was not possible, and missing data were thought to introduce serious bias, we would explore the impact of including such studies in the overall assessment of results by performing a sensitivity analysis. We would clearly describe any assumptions and imputations used to handle missing data and would explore the effect of imputation by performing sensitivity analyses. </p> <p>For dichotomous outcomes, we calculated event rates using the number of participants randomised in the group as the denominator. </p> <p>For continuous outcomes, we calculated the mean difference based on the number of participants analysed at that time point. If the number of participants analysed was not presented for each time point, we would use the number of randomised participants in each group at baseline. </p> <p>Where possible, we would compute missing standard deviations from other statistics such as standard errors, CIs, or P values, according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013130-bbs2-0081" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from handbook.cochrane.org.">Higgins 2021a</a>). If standard deviations could not be calculated, we would impute them (e.g. from other studies in the meta‐analysis). </p> </section> <section id="CD013130-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the case of sufficient included studies, we would perform meta‐regression to investigate potential sources of heterogeneity. We would assess clinical and methodological diversity in terms of participants, interventions, outcomes, and study characteristics for the included studies to determine whether a meta‐analysis was appropriate. We would do this using data from the data extraction tables. We would assess statistical heterogeneity by visually inspecting the forest plot for obvious differences in results between studies, and by performing I² and Chi² statistical tests. </p> <p>As recommended in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013130-bbs2-0068" title="DeeksJJ , HigginsJPT , AltmanDG .Chapter 10. Analyzing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Deeks 2022</a>), we would interpret the I² value as follows:  </p> <p> <ul id="CD013130-list-0009"> <li> <p>0% to 40%: might not be important; </p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity; </p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; </p> </li> <li> <p>75% to 100%: considerable heterogeneity. </p> </li> </ul> </p> <p>As noted in the <i>Cochrane Handbook</i> , we would keep in mind that the importance of I² depends on (1) the magnitude and direction of effects, and (2) the strength of evidence for heterogeneity. We would interpret the Chi² test with P ≤ 0.10 as indicating evidence of statistical heterogeneity. Had we identified substantial heterogeneity, we would have reported this and investigated possible causes by following the recommendations provided in Section 10.11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013130-bbs2-0068" title="DeeksJJ , HigginsJPT , AltmanDG .Chapter 10. Analyzing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD013130-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>In the case of sufficient included studies, we would perform tests to detect publication bias. We would create and examine a funnel plot to explore possible small‐study biases. In interpreting funnel plots, we would examine different possible reasons for funnel plot asymmetry as outlined in Section 13.3 of the <i>Cochrane Handbook,</i> and relate this to the review results. If we were able to pool more than 10 trials, we would undertake formal statistical tests to investigate funnel plot asymmetry, following the recommendations provided in Section 13.3 of the <i>Cochrane Handbook</i> (<a href="./references#CD013130-bbs2-0099" title="PageMJ , HigginsJPT , SterneJAC .Chapter 13. Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Page 2022</a>). </p> <p>To assess outcome reporting bias, we checked trial protocols against the published reports. When a protocol was not available, we would request access from study authors. If this was not obtainable, we would list the study as 'reporting bias cannot be ruled out'. For studies published after 1 July 2005, we would screen the WHO ICTRP (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for the a priori trial protocol. We would evaluate whether selective reporting of outcomes was present. </p> </section> <section id="CD013130-sec-0041"> <h4 class="title">Data synthesis</h4> <p>In the case of sufficient included studies, we would perform meta‐analysis, and only when this was meaningful (i.e. if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). We would analyse studies by grouping them according to study design, providing a global estimate in the context of the analysis of each study design. We did not pool together different measures of effect (e.g. odds ratio (OR) and RR). </p> <p>If meta‐analysis was possible, we would employ a random‐effects model using Review Manager 5 (<a href="./references#CD013130-bbs2-0107" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>) or RevMan Web (<a href="./references#CD013130-bbs2-0108" title="Review Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). Where meta‐analysis was not possible, we summarised results narratively including data from non‐comparative studies. </p> <p>When results were estimated for individual studies with low numbers of events (&lt; 10 in total), or when the total sample size was less than 30 participants and a risk ratio was used, we would report the proportion of events in each group together with a P value from Fisher’s exact test. </p> <p>In studies appraised using ROBINS‐I, we would exclude studies from pooled or narrative analysis if the ROBINS‐I assessment was critical.  </p> </section> <section id="CD013130-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analysis by category of disease severity (SCORTEN ≥ 3), body surface area (≥ 30%), advanced age (≥ 75 years), and co‐interventions if adequate data for meta‐analysis were available. </p> </section> <section id="CD013130-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>If adequate data were available for meta‐analysis, we would conduct sensitivity analyses to assess the robustness of data analysis, specifically to test the impact of the following. </p> <p> <ul id="CD013130-list-0010"> <li> <p>Treatment effect estimates that were unadjusted (because we believed this would help support our decision to exclude studies that did not adjust for important prespecified confounding variables, by showing that the results may change when this confounding is not accounted for). </p> </li> <li> <p>Missing data that required assumptions or imputations, or both.</p> </li> <li> <p>Studies with brief (less than one month) follow‐up.</p> </li> <li> <p>Quality assessment of the included studies (removing studies that were at high risk of bias or serious risk of bias). </p> </li> </ul> </p> </section> <section id="CD013130-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Based on our protocol, the most important comparisons of interventions that we sought to prepare the summary of findings tables were as follows. </p> <p> <ul id="CD013130-list-0011"> <li> <p>Etanercept versus cyclosporin</p> </li> <li> <p>Etanercept versus IVIG</p> </li> <li> <p>IVIG versus cyclosporin</p> </li> <li> <p>Cyclosporin versus corticosteroids</p> </li> </ul> </p> <p>However, of these comparisons, data were only available for IVIG versus cyclosporin. We therefore prepared summary of findings tables for the following comparisons.  </p> <p> <ul id="CD013130-list-0012"> <li> <p>Corticosteroids versus no corticosteroids </p> </li> <li> <p>IVIG versus no IVIG </p> </li> <li> <p>Etanercept versus corticosteroids</p> </li> <li> <p>Cyclosporin versus IVIG </p> </li> </ul> </p> <p>We included the following prespecified outcomes in each summary of findings table, where reported. </p> <section id="CD013130-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013130-list-0013"> <li> <p>Disease‐specific mortality</p> </li> <li> <p>Adverse events leading to discontinuation of therapy</p> </li> </ul> </p> </section> <section id="CD013130-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013130-list-0014"> <li> <p>Time to complete re‐epithelialisation</p> </li> <li> <p>ICU length of stay</p> </li> <li> <p>Total hospital length of stay</p> </li> </ul> </p> <p>For each summary of findings table, five review authors (AL, BO, RP, AJ, and JPP) independently assessed the quality of the evidence using the five GRADE considerations (study limitations/risk of bias based on the assessments from the risk of bias tools, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence (<a href="./references#CD013130-bbs2-0077" title="GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 5 June 2018. Available at gradepro.org.">GRADEpro GDT</a>). If only one study contributed to a comparison, the quality assessment was limited to data from the single study. We assessed the certainty of the evidence as high, moderate, low, or very low for each outcome. Evidence from RCTs is automatically assessed as high quality, with the certainty of the evidence downgraded for any of the factors listed above by one level (serious concerns) or two levels (very serious concerns). Evidence from observational studies also starts at high quality, whenever the ROBINS‐I tool is used. However, in all cases the evidence was downgraded two levels due to the inherent risk of bias associated with the lack of randomisation. However, we did consider the following criteria for upgrading the certainty of evidence, if appropriate: large effect, dose‐response gradient, and plausible confounding effect. We used the methods and recommendations described in Sections 8.5 and 8.7 and Chapters 14 and 15 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013130-bbs2-0068" title="DeeksJJ , HigginsJPT , AltmanDG .Chapter 10. Analyzing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD013130-bbs2-0071" title="DijkersM .Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development. ktdrr.org/products/update/v1n5/dijkers_grade_ktupdatev1n5.pdf (accessed prior to 5 June 2018).">Dijkers 2013</a>; <a href="./references#CD013130-bbs2-0081" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from handbook.cochrane.org.">Higgins 2021a</a>; <a href="./references#CD013130-bbs2-0114" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH .Chapter 14. Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence.  In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schunemann 2022a</a>; <a href="./references#CD013130-bbs2-0115" title="SchunemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al.Chapter 15. Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schunemann 2022b</a>). We justified all decisions to down‐ or upgrade the certainty of evidence using footnotes, and provided comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013130-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013130-sec-0047"></div> <section id="CD013130-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD013130-sec-0049"> <h4 class="title">Results of the search</h4> <p>Our search (see <a href="#CD013130-sec-0024">Search methods for identification of studies</a>) retrieved 6116 records. We removed 39 duplicates, and screened the remaining 6077 records. We excluded 5974 records based on titles and abstracts, and obtained the full texts of the remaining 103 records. We excluded 45 studies based on full‐text review (see <a href="./references#CD013130-sec-0112" title="">Characteristics of excluded studies</a>). We excluded another 43 studies after full‐text examination as our exclusion criteria developed (we restricted the review to only RCTs and prospective comparative studies, and excluded cross‐over trials). These studies can be viewed in a citation list at file repository <a href="https://osf.io/gth7c/?view_only=e0316ead836a436894a2e7c41346682a" target="_blank">https://osf.io/gth7c/?view_only=e0316ead836a436894a2e7c41346682a</a>. We identified three ongoing studies (see <a href="./references#CD013130-sec-0114" title="">Characteristics of ongoing studies</a>), and one completed but unpublished study (see <a href="./references#CD013130-sec-0113" title="">Characteristics of studies awaiting classification</a>). We included nine studies reported in 11 references in the qualitative synthesis. We included two studies in the quantitative synthesis (meta‐analysis). For a further description of our screening process, see the study flow diagram (<a href="#CD013130-fig-0002">Figure 2</a>). </p> </section> <section id="CD013130-sec-0050"> <h4 class="title">Included studies</h4> <section id="CD013130-sec-0051"> <h5 class="title">Design</h5> <p>We included three RCTs, <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a>; <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>; <a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a>, and six prospective, controlled observational studies, <a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>; <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>; <a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>; <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>; <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>; <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, in the review. </p> </section> <section id="CD013130-sec-0052"> <h5 class="title">Sample sizes</h5> <p>The nine studies included a total of 308 participants (range: 10 participants in <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a> to 91 participants in <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). There were 22 included participants in <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>; these data represent only the prospective data and were obtained directly from the study authors. </p> </section> <section id="CD013130-sec-0053"> <h5 class="title">Settings</h5> <p>Burn units in tertiary care hospitals were explicitly reported as the setting for <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a> (Madrid, Spain) and <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a> (Brussels, Belgium). An inpatient dermatology ward at a tertiary care centre in India served as the setting for <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> and <a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>; an inpatient referral centre for the largest medical system in Taiwan for <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>; an intensive care unit in a hospital in Xi'an, China for <a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>; an inpatient paediatrics ward in Athens, Greece for <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>; and a single‐centre inpatient hospital ward for <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>. <a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a> was set at nine hospitals across France. </p> </section> <section id="CD013130-sec-0054"> <h5 class="title">Participants</h5> <p>Across the nine included studies where demographic data were available, there were a total of 131 males and 155 females (sex distribution not available for <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>). Two studies included paediatric participants, with a total of 23 children represented (<a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>; <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>). The mean age of the participants in the adult trials (where available) ranged from 29 to 56 years. </p> <p>More specifically, participants in <a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a> had a mean age of 29.07 years, a sex distribution of 16 males versus 24 females, and a distribution of 29 SJS cases compared to 11 cases of TEN; body surface area (BSA) was not reported. The <a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a> study included both adults (n = 21) and children (n = 7), with 15 males and 13 females and a mean age of 25. The distribution of SJS/TEN or BSA was not reported. In <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>, participants had a mean age of 37 years, a sex distribution of 16 males versus 20 females, and a mean baseline BSA of 51.16%; all participants were reported to have TEN. <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a> included only paediatric participants, with 10 males and 6 females with a mean age ranging between 6 and 6.6 years; the distribution of SJS/TEN or BSA was not reported. Participants in <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a> had a mean age of 49 years, and 8 of 10 participants were female; mean BSA at baseline was 44.5%, with all participants diagnosed with TEN. In <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, reported baseline characteristics of the study population were 56% aged 20 to 39 years and 51% male, with 21 participants categorised as having SJS, 11 as SJS/TEN overlap, and 11 as TEN; BSA was not reported. The <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> study reported a mean age of 56.09 years, and a predominance of females: 51 females and 40 males, with the majority of cases (61.5%) classified as having less than 10% BSA affected; the distribution of SJS/TEN was not reported. Finally, participants in <a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a> had an age range of 23 to 81 years, a sex distribution of 10 males and 12 females, and a range of BSA at baseline of 10% to 90%; a distinction between SJS/TEN overlap and TEN was not reported. </p> <p>Demographics of the participants from the prospective data, which were obtained directly from the authors of <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, were not available. SCORTEN for participants was reported in <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> (mean: 3, range: 2 to 3) and <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> (mean: 1.90). </p> </section> <section id="CD013130-sec-0055"> <h5 class="title">Interventions</h5> <p>Our main comparisons of interest, as specified in the review protocol, included: etanercept versus cyclosporin, etanercept versus IVIg, IVIg versus supportive care, IVIG versus cyclosporin, and cyclosporin versus corticosteroids. However, we identified no studies that directly made these comparisons. Some studies included more than one comparison, whilst others compared an intervention to supportive care alone. Most studies did not specify the exact supportive care measures provided. Only two studies reported on hospital follow‐up after discharge (<a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>; <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). We included the following comparisons in this review. </p> <p> <ul id="CD013130-list-0015"> <li> <p>Corticosteroids versus no corticosteroids</p> </li> <li> <p>IVIG versus no IVIG</p> </li> <li> <p>Etanercept versus corticosteroids</p> </li> <li> <p>Cyclosporin versus IVIG</p> </li> <li> <p>N‐acetylcysteine and infliximab versus infliximab alone</p> </li> <li> <p>Thalidomide versus placebo</p> </li> <li> <p>Plasmapheresis versus other treatments</p> </li> </ul> </p> <p>The interventions of interest are listed below along with their corresponding studies. Please note that studies may be repeated between groups due to multiple comparisons. </p> <section id="CD013130-sec-0056"> <h6 class="title">Cyclosporin</h6> <p>In <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a> (n = 22), cyclosporin was compared to other treatments including IVIG (n = 4), systemic corticosteroids (n = 1), or no specified treatment (n = 1). Cyclosporin was dosed at oral 3 mg/kg/day or intravenous (IV) 1 mg/kg/day until complete re‐epithelialisation, then tapered off (10 mg/day reduction every 48 hours). IVIG in the <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a> study was infused continuously at a dose of 0.75 g/kg/day for four days (total dose = 3 g/kg) in participants with normal renal function (a lower dose was used in participants with renal insufficiency). Finally, a systemic corticosteroid dose of prednisone‐equivalent dose ranging from 37.5 to 100 mg for 9 to 12 days was used. We identified no additional studies with a cyclosporin comparison arm. </p> </section> <section id="CD013130-sec-0057"> <h6 class="title">Corticosteroids</h6> <p>Five studies involved comparisons of corticosteroids. In <a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a> (n = 40), corticosteroids were compared to supportive care; however, details on dose, duration, and the specifics of supportive care measures were not reported. <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> (n = 36) compared IVIG plus corticosteroids to supportive care plus corticosteroids. IVIG in this study was dosed at 0.2 to 0.5 g/kg cumulative dose divided over three days, whilst IV dexamethasone 0.1 to 0.3 mg/kg/day was rapidly tapered within one to two weeks according to response. Participants in the <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> study were scheduled for a six‐month visit after hospital discharge for follow‐up. <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a> (n = 43) also considered both corticosteroids and IVIG, comparing IVIG versus IVIG plus corticosteroids versus supportive care alone; dosages and duration were not available. <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a> (n = 16) compared corticosteroids to supportive care alone, with the dose of methylprednisolone described as a bolus infusion of 4 mg/kg/day for two more days after fever had subsided and no new lesions had developed. Details on supportive care measures for <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a> included topical saline compresses and sprays, petroleum jelly, bathing, topical lidocaine gel to the oral mucosa, and topical antibiotics and artificial tears to the eyes. Finally, <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> (n = 91) compared etanercept to corticosteroids. Etanercept was dosed at 25 mg (50 mg if weight &gt; 65 kg) subcutaneously twice weekly "until skin lesions healed", whilst IV prednisolone 1 to 1.5 mg/kg/day was given "until skin lesions healed". Participants in the <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> study were followed until three weeks post‐hospital discharge. </p> </section> <section id="CD013130-sec-0058"> <h6 class="title">Etanercept</h6> <p><a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> (n = 91) evaluated a comparison including etanercept for treatment of SJS/TEN (see details above under 'Corticosteroids'). </p> </section> <section id="CD013130-sec-0059"> <h6 class="title">IVIG</h6> <p>Two studies, <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> and <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, evaluated IVIG as a comparator (see details above under 'Corticosteroids'). </p> </section> <section id="CD013130-sec-0060"> <h6 class="title">Other interventions</h6> <p>We identified three studies matching our inclusion criteria but not our prespecified systemic interventions of interest. No summary of findings tables were constructed for these comparisons, but the interventions are described here. In <a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a> (n = 28), plasmapheresis was compared to non‐plasmapheresis treatments including IVIG or corticosteroids, or both. Plasmapheresis was dosed as a one‐time dose of 1000 mL of Ringer‐Locke and 2000 to 3000 mL of plasma at a rate of 1000 mL an hour. No details on the dosages of IVIG or corticosteroids were provided. </p> <p>In <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a> (n = 10), infliximab combined with IV N‐acetylcysteine was compared to IV N‐acetylcysteine alone. Infliximab was given at 5 mg/kg intravenously over a two‐hour period. N‐acetylcysteine was diluted in 5% glucose solution and given intravenously over a 20‐hour period (150 mg/kg in 250 mL of solution during the first hour, followed by 150 mg/kg in 500 mL during a 4‐hour period, and finally 150 mg/kg in 1000 mL for 15 hours). </p> <p>Finally, in <a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a> (n = 22), thalidomide (200 mg by mouth twice a day for 5 days) was compared to placebo given at the same frequency and duration. Participants were followed for up to seven days after treatment. </p> </section> </section> <section id="CD013130-sec-0061"> <h5 class="title">Outcomes</h5> <p>The two primary outcomes of this review were disease‐specific mortality and adverse events leading to discontinuation. No disease‐specific mortality data were reported for <a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>, and it was not possible to extract the supplied mortality data in <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a> for analysis; however, all other studies reported this outcome. Also, no studies reported on adverse effects leading to discontinuation of therapy. </p> <p>Reporting on secondary outcomes was inconsistent, with only two studies providing data on time to complete re‐epithelialisation (<a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>; <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). Two studies reported total hospital length of stay (<a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>; <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>). <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> reported on illness sequelae. <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> and <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> reported on other adverse events. </p> <p>Two studies reported participant follow‐up after hospital discharge, one at three weeks, <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>, and the other at six months (<a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>). Timing of outcome assessment was not reported. </p> <p>No studies measured ICU length of stay.</p> </section> <section id="CD013130-sec-0062"> <h5 class="title">Funding sources</h5> <p>Four studies reported funding sources, which included a research grant from the Instituto de Salud Carlos III–Ministerio de Economía, Industria y Competitividad (<a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>), the Scientific Fund for the Young Talent of Shaanxi Province (<a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>), a grant from Fonds d'Investissement de la Recherche Scientifique of the University Hospital of Liege (<a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a>), and grants from the National Science Council of Taiwan and Ministry of Health and Welfare of Taiwan (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). In one study (<a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a>), free samples of the study drug (infliximab) were provided by industry. </p> </section> </section> <section id="CD013130-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We excluded 45 studies (see <a href="./references#CD013130-sec-0112" title="">Characteristics of excluded studies</a>). We excluded 44 of these due to wrong study design. We excluded one prospective study comparing IVIG to supportive care (<a href="./references#CD013130-bbs2-0021" title="Editors.Erratum. Journal of the American Academy of Dermatology2013;69(6):1048. Editors.Expression of Concern. Journal of the American Academy of Dermatology2014;71(3):583. [PMID: 24976444]FirozBF , HenningJS , ZarzabalLA , PollockBH .Toxic epidermal necrolysis: five years of treatment experience from a burn unit. Journal of the American Academy of Dermatology2012;67(4):630-5. ">Firoz 2012</a>). The <i>Journal of the American Academy of Dermatology</i> published an erratum stating that institutional review board approval was not obtained as stated in the paper (<a href="./references#CD013130-bbs2-0021" title="Editors.Erratum. Journal of the American Academy of Dermatology2013;69(6):1048. Editors.Expression of Concern. Journal of the American Academy of Dermatology2014;71(3):583. [PMID: 24976444]FirozBF , HenningJS , ZarzabalLA , PollockBH .Toxic epidermal necrolysis: five years of treatment experience from a burn unit. Journal of the American Academy of Dermatology2012;67(4):630-5. ">Firoz 2012</a>). An expression of concern was also published that reported of a significant discrepancy between the number of patients recorded in the hospital database as having SJS/TEN and those reported in the paper. Furthermore, the original paper states that all diagnoses were biopsy‐confirmed, but only 75% of patients are recorded in the hospital database as having a confirmatory biopsy (<a href="./references#CD013130-bbs2-0021" title="Editors.Erratum. Journal of the American Academy of Dermatology2013;69(6):1048. Editors.Expression of Concern. Journal of the American Academy of Dermatology2014;71(3):583. [PMID: 24976444]FirozBF , HenningJS , ZarzabalLA , PollockBH .Toxic epidermal necrolysis: five years of treatment experience from a burn unit. Journal of the American Academy of Dermatology2012;67(4):630-5. ">Firoz 2012</a>). Based on this information, we decided to exclude this study. </p> <p>We also excluded 43 other studies after full‐text examination as our exclusion criteria developed (we restricted the review to only RCTs and prospective comparative studies, and excluded cross‐over trials). These studies can be viewed in a citation list at file repository <a href="https://osf.io/gth7c/?view_only=e0316ead836a436894a2e7c41346682a" target="_blank">https://osf.io/gth7c/?view_only=e0316ead836a436894a2e7c41346682a</a>. </p> <section id="CD013130-sec-0064"> <h5 class="title">Ongoing studies</h5> <p>We identified a further three ongoing studies (see <a href="./references#CD013130-sec-0114" title="">Characteristics of ongoing studies</a>). Two RCTs are comparing granulocyte colony‐stimulating factor with placebo (<a href="./references#CD013130-bbs2-0056" title="NCT02739295.G-CSF in the treatment of toxic epidermal necrolysis. clinicaltrials.gov/ct2/show/NCT02739295 (first received 15 April 2016). ">NCT02739295</a>), and cyclosporin versus etanercept versus supportive care (<a href="./references#CD013130-bbs2-0057" title="NCT02987257.NATIENS: Optimal management and mechanisms of SJS/TEN (NATIENS). clinicaltrials.gov/show/NCT02987257 (first received 8 December 2016). ">NCT02987257</a>). One prospective cohort study is evaluating cyclosporin, IVIG, etanercept, and steroids (<a href="./references#CD013130-bbs2-0058" title="NCT03585946.Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis. clinicaltrials.gov/show/NCT03585946 (first received 13 July 2018). ">NCT03585946</a>). </p> </section> <section id="CD013130-sec-0065"> <h5 class="title">Studies awaiting classification</h5> <p>One study comparing glucocorticoid alone to glucocorticoid plus IVIG is finished but not yet published (<a href="./references#CD013130-bbs2-0055" title="ChiCTR-TRC-13003550.Use of glucocorticoid alone or plus intravenous immunoglobulin(IVIG) for the treatment of severe drug eruption. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-13003550 (first received 3 September 2013). ">ChiCTR‐TRC‐13003550</a>), so is awaiting classification (see <a href="./references#CD013130-sec-0113" title="">Characteristics of studies awaiting classification</a>). </p> </section> </section> </section> <section id="CD013130-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD013130-sec-0067"> <h4 class="title">Randomised controlled trials </h4> <p>We assessed three RCTs, <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a>; <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>; <a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a>, for risk of bias using Cochrane’s RoB 2 tool (<a href="./references#CD013130-bbs2-0082" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC .Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>; <a href="./references#CD013130-bbs2-0121" title="Sterne JAC,  Savović J,  Page MJ,  Elbers RG,  Blencowe NS,  Boutron I, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). See the risk of bias summary (<a href="#CD013130-fig-0003">Figure 3</a>) and the risk of bias in each study for each domain for the outcome of mortality (<a href="#CD013130-fig-0004">Figure 4</a>). Please also see the interactive RoB 2 tables for each analysis (<a href="./references#CD013130-tblf-0015" title="">Risk of bias table for Analysis 3.1</a>; <a href="./references#CD013130-tblf-0016" title="">Risk of bias table for Analysis 5.1</a>; <a href="./references#CD013130-tblf-0017" title="">Risk of bias table for Analysis 6.1</a>). Detailed assessment notes and responses to the signal questions are available <a href="https://osf.io/gth7c/?view_only=e0316ead836a436894a2e7c41346682a" target="_blank">here</a>. </p> <div class="figure" id="CD013130-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="RoB 2 summary." data-id="CD013130-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>RoB 2 summary.</p> </div> </div> </div> <div class="figure" id="CD013130-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias judgements for RCTs using the RoB 2 tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study." data-id="CD013130-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias judgements for RCTs using the RoB 2 tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study. </p> </div> </div> </div> <p>For disease‐specific mortality, risk of bias was low in all domains and overall for <a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a>. However, we assessed <a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a> as at high risk of bias related to the randomisation process, and some concerns due to deviations from the intended interventions and selection of the reported result, therefore the risk of bias overall for this outcome was high. We assessed <a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> as some concerns related to the selection of the reported result; overall the risk of bias was some concerns. </p> </section> <section id="CD013130-sec-0068"> <h4 class="title">Non‐randomised trials</h4> <section id="CD013130-sec-0069"> <h5 class="title">Prospective observational controlled studies </h5> <p>We assessed five prospective observational controlled studies, <a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>; <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>; <a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>; <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>; <a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>, for risk of bias using the ROBINS‐I tool as developed by members of the Cochrane Non‐Randomized Studies for Interventions Methods Group (<a href="./references#CD013130-bbs2-0120" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al.ROBINS-1: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [PMID: 27733354]">Sterne 2016</a>). For individual assessments of each study, see <a href="#CD013130-tbl-0014">Table 4</a> and <a href="#CD013130-fig-0005">Figure 5</a> for the outcome disease‐specific mortality; <a href="#CD013130-tbl-0015">Table 5</a> and <a href="#CD013130-fig-0006">Figure 6</a> for days to full skin healing; and <a href="#CD013130-tbl-0016">Table 6</a> and <a href="#CD013130-fig-0007">Figure 7</a> for hospital length of stay. We assessed all outcome results as overall serious risk bias. The major concerns were confounding not having been addressed and bias in the classification of interventions. <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a> did not contribute to any of the outcomes, so we were not able to assess risk of bias using ROBINS‐I. </p> <div class="table" id="CD013130-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: disease‐specific mortality</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of the reported result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b><a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b>  </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on most confounders ‐ unclear if comparable between groups<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided ‐ cannot determine from study text.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention status was likely determined in such a way that could have been affected by knowledge of the outcome.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in study text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data available for all reported outcomes for all participants.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.<br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most confounding variables accounted for, apart from duration of follow‐up.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All consecutive patients over the age of 14 who fulfilled diagnostic criteria during the study time period were included in the study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided on how intervention assignment took place within each burn unit. <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors provided mortality data on all prospectively recruited patients.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on some confounders ‐ unclear if comparable between study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutively diagnosed patients during the study period were included in the study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided on how intervention assignment took place other than alternate allocation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were available for all participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was disease‐specific mortality, which is an objective measure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study assessed various outcomes of interest; this risk of bias analysis relates to disease‐specific mortality. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on most confounders ‐ unclear if comparable between study groups<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided ‐ cannot determine from text.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very few details provided on intervention groups and how group assignment took place.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear from information provided in text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific mortality is the only outcome of interest in this study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific mortality is the only outcome of interest in this study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.<br/>  </p> </td> </tr> </tbody> </table> </div> <div class="figure" id="CD013130-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study. " data-id="CD013130-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study.  </p> </div> </div> </div> <div class="table" id="CD013130-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: days to full skin healing</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of the reported result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on some confounders ‐ unclear if comparable between study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutively diagnosed patients during the study period were included in the study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided on how intervention assignment took place, other than alternate allocation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were available for all participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concerns due to non‐blinding: evaluations and outcome measurement could have been influenced by knowledge of treatment allocation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No prespecified analysis plan was reported as finalised before unblinded data were available for analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> </tbody> </table> </div> <div class="figure" id="CD013130-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: time to complete re‐epithelialisation. Follow‐up: end of study. " data-id="CD013130-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-06.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: time to complete re‐epithelialisation. Follow‐up: end of study.  </p> </div> </div> </div> <div class="table" id="CD013130-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: hospital length of stay</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of the reported result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on most confounders ‐ unclear if comparable between study groups<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided ‐ cannot determine from article.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very few details provided on intervention groups and how group assignment took place: “divided into two groups on the basis of whether plasma exchange was performed after admission”.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in study text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported on hospital length of stay for each participant in supplementary table.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information about outcome assessors and whether they were blinded was not provided.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual patient data and outcomes provided in supplementary material.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on some confounders ‐ unclear if comparable between study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutively diagnosed patients during the study period were included in the study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided on how intervention assignment took place, other than alternate allocation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were available for all participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concerns due to non‐blinding: evaluations and outcome measurement could have been influenced by knowledge of treatment allocation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No prespecified analysis plan was reported as finalised before unblinded data were available for analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> </tbody> </table> </div> <div class="figure" id="CD013130-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: total hospital length of stay. Follow‐up: end of study. " data-id="CD013130-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: total hospital length of stay. Follow‐up: end of study.  </p> </div> </div> </div> </section> </section> </section> <section id="CD013130-sec-0070"> <h3 class="title" id="CD013130-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD013130-tbl-0001"><b>Summary of findings 1</b> Corticosteroids compared to no corticosteroids</a>; <a href="./full#CD013130-tbl-0002"><b>Summary of findings 2</b> Intravenous immunoglobulin (IVIG) compared to no IVIG</a>; <a href="./full#CD013130-tbl-0003"><b>Summary of findings 3</b> Etanercept compared to no etanercept</a>; <a href="./full#CD013130-tbl-0004"><b>Summary of findings 4</b> Cyclosporin compared to no cyclosporin</a>; <a href="./full#CD013130-tbl-0005"><b>Summary of findings 5</b> Intravenous immunoglobulin (IVIG) compared to corticosteroids</a>; <a href="./full#CD013130-tbl-0006"><b>Summary of findings 6</b> Etanercept compared to corticosteroids</a>; <a href="./full#CD013130-tbl-0007"><b>Summary of findings 7</b> Cyclosporin compared to corticosteroids</a>; <a href="./full#CD013130-tbl-0008"><b>Summary of findings 8</b> Etanercept compared to intravenous immunoglobulin (IVIG)</a>; <a href="./full#CD013130-tbl-0009"><b>Summary of findings 9</b> Cyclosporin compared to intravenous immunoglobulin (IVIG)</a>; <a href="./full#CD013130-tbl-0010"><b>Summary of findings 10</b> Etanercept compared to cyclosporin</a> </p> <p>There were available data for only seven comparisons, details of which are described below. </p> <p> <ul id="CD013130-list-0016"> <li> <p>Corticosteroids versus no corticosteroids</p> </li> <li> <p>IVIG versus no IVIG</p> </li> <li> <p>Etanercept versus corticosteroids</p> </li> <li> <p>Cyclosporin versus IVIG</p> </li> <li> <p>N‐acetylcysteine and infliximab versus infliximab alone</p> </li> <li> <p>Thalidomide versus placebo</p> </li> <li> <p>Plasmapheresis versus other treatments</p> </li> </ul> </p> <p>It was not possible to pool studies for any of the comparisons, which precluded subgroup or sensitivity analyses. </p> <section id="CD013130-sec-0071"> <h4 class="title">Corticosteroids versus no corticosteroids </h4> <p>The evidence is very uncertain regarding the effect of corticosteroids on disease‐specific mortality compared to supportive care. One prospective study with 16 participants reported zero events (<a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>). Evidence from a second prospective study with 40 participants resulted in a risk ratio (RR) of 2.55 (95% confidence interval (CI) 0.72 to 9.03; very low‐certainty evidence; <a href="./references#CD013130-fig-0008" title="">Analysis 1.1</a>; Fisher's exact test P = 0.25) (<a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>). There were 141 more deaths out of a thousand with corticosteroids compared to supportive care (95% CI 26 fewer deaths to 730 more). In <a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>, data for mortality were available separately for SJS (RR 3.83, 95% CI 0.67 to 21.88) and TEN (RR 1.71, 95% CI 0.26 to 11.47) respectively, but a formal subgroup analysis was not possible due to the small numbers of participants. See <a href="./references#CD013130-fig-0008" title="">Analysis 1.1</a>.   </p> <p>Data were not available for ICU length of stay, total hospital length of stay, time to complete re‐epithelialisation, withdrawal due to adverse events, or other adverse events.  </p> <p>See <a href="./full#CD013130-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD013130-sec-0072"> <h4 class="title">IVIG versus no IVIG</h4> <p>The evidence is very uncertain regarding the effect of IVIG (plus corticosteroids) compared to no IVIG (corticosteroids alone) on disease‐specific mortality (RR 0.33, 95% CI 0.04 to 2.91; 1 observational study; 36 participants; very low‐certainty evidence; <a href="./references#CD013130-fig-0009" title="">Analysis 2.1</a>; Fisher's exact test P = 0.60). There were 11.2% fewer deaths with IVIG plus corticosteroids compared to corticosteroids alone (95% CI 16% fewer to 31.8% more). There was a 67% lower risk of mortality with IVIG plus corticosteroids compared to corticosteroids alone (<a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>). </p> <p>The evidence is very uncertain regarding the effect of IVIG plus corticosteroids compared to corticosteroids alone for the following outcomes: time to complete re‐epithelialisation (days to full skin healing, mean difference (MD) −2.93, 95% CI −4.40 to −1.46; 1 observational study; 36 participants; very low‐certainty evidence; <a href="./references#CD013130-fig-0010" title="">Analysis 2.2</a>) and total hospital length of stay (days, MD −2.00, 95% CI −5.81 to 1.81; 1 observational study; 36 participants; very low‐certainty evidence; <a href="./references#CD013130-fig-0011" title="">Analysis 2.3</a>) (<a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a>). This study qualitatively reports the outcome illness sequelae, but does not state in which treatment group the complications occurred. This study also qualitatively reports other adverse events, but does not state in which treatment group the complications occurred. The authors note that bacterial infections was the most common complication encountered overall. </p> <p>Data were not available for ICU length of stay or withdrawal due to adverse events.</p> <p><a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a> had three participants on IVIG plus corticosteroids and 10 participants on intravenous corticosteroids. This study also included participants on IVIG alone and supportive care alone. Although this study provided mortality data, it was not possible to extract the data for this analysis. </p> <p>See <a href="./full#CD013130-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD013130-sec-0073"> <h4 class="title">Etanercept versus no etanercept</h4> <p>No trials were identified for this comparison. See <a href="./full#CD013130-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD013130-sec-0074"> <h4 class="title">Cyclosporin versus no cyclosporin</h4> <p>No trials were identified for this comparison. See <a href="./full#CD013130-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD013130-sec-0075"> <h4 class="title">IVIG versus corticosteroids</h4> <p>No trials were identified for this comparison. See <a href="./full#CD013130-tbl-0005">summary of findings Table 5</a>. </p> </section> <section id="CD013130-sec-0076"> <h4 class="title">Etanercept versus corticosteroids</h4> <p>Etanercept may reduce disease‐specific mortality compared to corticosteroids (RR 0.51, 95% CI 0.16 to 1.63; 1 RCT; 91 participants; low‐certainty evidence; <a href="./references#CD013130-fig-0012" title="">Analysis 3.1</a>). There were 8% fewer deaths with etanercept compared to corticosteroids (95% CI 13.7% fewer to 10.3% more). There was a 49% lower risk of mortality with etanercept compared to corticosteroids (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>).  </p> <p>We assessed the overall risk of bias for this result as some concerns due to concerns about bias in selection of the reported result, as mortality was not specified as an outcome in the trial registry record. </p> <p><a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a> reported that 5 of 48 participants in the etanercept group experienced serious adverse events (sepsis, respiratory failure, and bipolar disorder), and 9 of 43 participants in the corticosteroids group (sepsis, respiratory failure, upper gastrointestinal haemorrhage, stridor and vocal cord palsy). It is unclear from the trial report if any of these adverse events led to discontinuation of treatment. The authors also report that in participants with 10% or greater BSA detachment, the time to complete skin healing was significantly shorter in the etanercept‐treated group compared to the corticosteroid‐treated group (P = 0.010, by Kaplan‐Meier analysis), with the median time to skin healing 14 and 19 days, respectively.  </p> <p>Data were not available for ICU length of stay, time to complete re‐epithelialisation, or total hospital length of stay. </p> <p>See <a href="./full#CD013130-tbl-0006">summary of findings Table 6</a>. </p> </section> <section id="CD013130-sec-0077"> <h4 class="title">Cyclosporin versus corticosteroids</h4> <p>No trials were identified for this comparison. See <a href="./full#CD013130-tbl-0007">summary of findings Table 7</a>. </p> </section> <section id="CD013130-sec-0078"> <h4 class="title">Etanercept versus IVIG</h4> <p>No trials were identified for this comparison. See <a href="./full#CD013130-tbl-0008">summary of findings Table 8</a>. </p> </section> <section id="CD013130-sec-0079"> <h4 class="title">Cyclosporin versus IVIG</h4> <p>One cohort study with 22 prospective patients provided data for this comparison on the following prespecified outcome: disease‐specific mortality (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046) (<a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). </p> <p>Data were not available for ICU length of stay, total hospital length of stay, time to complete re‐epithelialisation, withdrawal due to adverse events, or other adverse events. We assessed risk of bias as some concerns due to potential confounding effects and selection bias. </p> <p>See <a href="./full#CD013130-tbl-0009">summary of findings Table 9</a>. </p> </section> <section id="CD013130-sec-0080"> <h4 class="title">Etanercept versus cyclosporin</h4> <p>No trials were identified for this comparison. See <a href="./full#CD013130-tbl-0010">summary of findings Table 10</a>. </p> </section> <section id="CD013130-sec-0081"> <h4 class="title">N‐acetylcysteine and infliximab versus infliximab alone</h4> <p>One small RCT with 10 participants provided data for this comparison on the following prespecified outcome: disease‐specific mortality (RR 2.00, 95% CI 0.26 to 15.62; <a href="./references#CD013130-fig-0014" title="">Analysis 5.1</a>; Fisher's exact test P = 1.00) (<a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a>). Characterisation of participant deaths included events up to 10 days after initiation of therapy. Otherwise, time to follow‐up was not reported. The overall risk of bias for this result was high due to concerns about bias arising from the randomisation process. </p> <p>Data were not available for ICU length of stay, total hospital length of stay, time to complete re‐epithelialisation, withdrawal due to adverse events, or other adverse events. </p> </section> <section id="CD013130-sec-0082"> <h4 class="title">Thalidomide versus placebo</h4> <p>One RCT provided data for this comparison on the following prespecified outcome: disease‐specific mortality (RR 2.78, 95% CI 1.04 to 7.40; <a href="./references#CD013130-fig-0015" title="">Analysis 6.1</a>; Fisher's exact test P = 0.027) (<a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a>). Participants were followed for up to seven days after treatment or death if it occurred sooner. The overall risk of bias for this result was low. </p> <p>Data were not available for ICU length of stay, total hospital length of stay, time to complete re‐epithelialisation, withdrawal due to adverse events, or other adverse events. </p> </section> <section id="CD013130-sec-0083"> <h4 class="title">Plasmapheresis versus other treatments</h4> <p>One prospective study with 28 participants provided data for this comparison on the following prespecified outcome: total hospital length of stay (days, MD −7.37, 95% CI −16.09 to 1.35; <a href="./references#CD013130-fig-0016" title="">Analysis 7.1</a>) (<a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a>). Participants were followed from admission to hospital discharge.  </p> <p>Data were not available for disease‐specific mortality, ICU length of stay, time to complete re‐epithelialisation, withdrawal due to adverse events, or other adverse events. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013130-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013130-sec-0084"></div> <section id="CD013130-sec-0085"> <h3 class="title" id="CD013130-sec-0085">Summary of main results</h3> <p>We included nine studies with a total of 308 participants, including adults and children, from seven countries. We included two of these studies in the quantitative meta‐analysis. </p> <p>We included three RCTs and six prospective, controlled observational studies. Only one of the randomised trials was considered as at low risk of bias overall (<a href="./references#CD013130-bbs2-0009" title="WolkensteinP , LatargetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: overmortality in treated group. Journal of Dermatological Science1998;16(Suppl 1):S44. [DOI: 10.1016/S0923-1811(98)83259-3]WolkensteinP , LatarjetJ , RoujeauJC , DuguetC , BoudeauS , VaillantL , et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet1998;352(9140):1586-9. ">Wolkenstein 1998</a>). Of the other two, one was judged at high risk of bias overall due to bias arising from the randomisation process and some concerns due to deviations from the intended interventions and selection of the reported result (<a href="./references#CD013130-bbs2-0006" title="PaquetP , JennesS , RousseauAF , LibonF , DelvenneP , PiérardGE .Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns2014;40(8):1707-12. [DOI: 10.1016/j.burns.2014.01.027]">Paquet 2014</a>). For the other RCT, we made a risk of bias assessment of some concerns due to selection of the reported result (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). All risk of bias assessments for the RCTs related to the outcome disease‐specific mortality. For the five observational studies included in the analysis, all outcome results (i.e. disease‐specific mortality, days to full skin healing, and length of hospital stay) were considered at overall serious risk bias; the major concerns were not addressing confounding and bias in the classification of interventions. </p> <p>We found very low‐certainty evidence for the outcome of mortality in the following comparisons: corticosteroids versus no corticosteroids (two observational studies, 56 participants, <a href="./full#CD013130-tbl-0001">summary of findings Table 1</a>); IVIG versus no IVIG (one observational study, 36 participants, <a href="./full#CD013130-tbl-0002">summary of findings Table 2</a>); and cyclosporin versus IVIG (one observational study, 22 participants, <a href="./full#CD013130-tbl-0009">summary of findings Table 9</a>). Hence, we are uncertain of the effect of these treatment comparisons. </p> <p>For the comparison of IVIG versus no IVIG, we found only very low‐certainty evidence for the secondary outcomes reduction in time to complete re‐epithelialisation and reduction in total hospital length of stay (one observational study, 36 participants,<b> </b><a href="./full#CD013130-tbl-0002">summary of findings Table 2</a>), therefore we are uncertain of their effects. These outcomes were not measured for the comparisons of corticosteroids versus no corticosteroids and cyclosporin versus IVIG. </p> <p>Based on one study with 91 participants, etanercept may decrease mortality when compared to corticosteroids; however, the 95% CI was wide and included null (low‐certainty evidence). Serious adverse events, such as sepsis and respiratory failure, were reported in both groups, but it was not clear if they led to discontinuation of treatment (<a href="./full#CD013130-tbl-0006">summary of findings Table 6</a>). No other key treatment comparison measured adverse effects leading to discontinuation of SJS/TEN therapy. Time to complete re‐epithelialisation and length of hospital stay were not reported. </p> <p>We did not find any studies addressing our most important comparisons: cyclosporin versus corticosteroids (<a href="./full#CD013130-tbl-0007">summary of findings Table 7</a>), etanercept versus IVIG (<a href="./full#CD013130-tbl-0008">summary of findings Table 8</a>), cyclosporin versus IVIG (<a href="./full#CD013130-tbl-0009">summary of findings Table 9</a>), or etanercept versus cyclosporin (<a href="./full#CD013130-tbl-0010">summary of findings Table 10</a>). </p> <p>No studies measured ICU length of stay.</p> </section> <section id="CD013130-sec-0086"> <h3 class="title" id="CD013130-sec-0086">Overall completeness and applicability of evidence</h3> <p>The nine studies included in this review were conducted in a diverse variety of settings, including India, Taiwan, Europe, and China. No studies based in other countries met the inclusion criteria. Study locations included inpatient dermatology wards, an ICU, and burns units, which represent the typical setting where such patients would be treated. We found no studies of our prespecified comparisons between systemic therapies of interest including cyclosporin, etanercept, and IVIG, nor for cyclosporin versus corticosteroids. Comparisons between the above systemic agents versus corticosteroids or supportive care were more commonly represented in our included studies; however, the way in which data were presented and analysed made comparisons unfeasible. The included studies were not able to fully address the objective of this review to assess the effects of all systemic therapies for the treatment of SJS, TEN, and SJS/TEN overlap syndrome. None of the interventions was very well assessed: corticosteroids versus supportive care was the only comparison assessed by more than one study. </p> <p>Only two studies included paediatric participants, and we were unable to perform subgroup analyses of mortality between paediatric and adult participants in this review. The participants in four studies had a mean age under 40 years, and the other two studies that reported participant mean age had means of 49 and 56 years. A skew towards adult age is expected, as this represents an increasing use of drugs associated with SJS‐TEN in the population overall. Separate data were not provided for elderly adults.  </p> <p>Seven studies reported extractable mortality data but with very limited data on other outcomes or adverse events. Only two studies reported on adverse events, and no studies reported our primary outcome of adverse events leading to discontinuation of SJS/TEN therapy. None of the studies reported on length of stay in ICU or illness sequelae, although one study reported overall illness sequelae for all participants. Three studies reported on time to re‐epithelialisation, and two on length of stay in hospital. </p> <p>Reporting of the key prognostic characteristics of the included participants was, in general, poor. Specifically, SCORTEN was not consistently reported between studies, which has implications for predicting mortality. For example, a SCORTEN of 0 to 1 is associated with a predicted mortality rate of 3.2%, whereas scores of ≥ 5 are associated with a predicted mortality rate of 90% (<a href="./references#CD013130-bbs2-0062" title="Bastuji-GarinS , FouchardN , BertocchiM , RoujeauJC , RevuzJ , WolkensteinP .SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. Journal of Investigative Dermatology2000;115(2):149-53. [PMID: 10951229]">Bastuji‐Garin 2000</a>). Other reporting of severity, such as BSA affected, was only available for three studies, with means ranging from 44% to 51%. One study simply reported that 61.5% of the participants had more than 10% of BSA. Reporting of age or sex was done at baseline for most studies, but not always addressed in the analysis. Only two studies reported baseline comorbidities. </p> <p>Due to the paucity of data, it was not possible to perform any of the following planned subgroup analyses: disease severity (SCORTEN ≥ 3), BSA (≥ 30%), advanced age (≥ 75 years), and co‐interventions. </p> <p>We identified three ongoing randomised trials, and one completed study awaiting assessment.</p> </section> <section id="CD013130-sec-0087"> <h3 class="title" id="CD013130-sec-0087">Quality of the evidence</h3> <p>We did not find any studies addressing the main comparisons of interest. Of the comparisons for which data were available, the studies were generally small and at high risk of bias. Most of the evidence was from observational studies, and there were concerns regarding selection bias and lack of controlling for confounders. Data were generally sparse, and in most cases, mortality was the only outcome properly reported. We assessed the evidence for all outcome results, apart from one, to be of very low certainty, mainly due to imprecision (small studies and wide confidence intervals). Hence, we are uncertain about the results for these comparisons. The comparison of etanercept versus corticosteroids (<a href="./full#CD013130-tbl-0006">summary of findings Table 6</a>) was based on one RCT and was judged to be low certainty of evidence for mortality. We downgraded the evidence twice due to imprecision, firstly for being based on a small study with few participants, and secondly for having a wide confidence interval that included important benefits and increased risk of harms. Despite the study being unblinded, we decided not to downgrade further, as we considered it unlikely to influence an objective measure such as mortality. We did not downgrade any results for heterogeneity, indirectness, or publication bias.  </p> </section> <section id="CD013130-sec-0088"> <h3 class="title" id="CD013130-sec-0088">Potential biases in the review process</h3> <p>During the process of the review, we made several decisions that could affect the results. First, we decided to further restrict our inclusion criteria to only RCTs and prospective, comparative studies. This decision limited the number of participants that could be included from the <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a> study. They conducted a retrospective‐prospective study, taking advantage of the two units that covered most patients from Madrid. Each of these centres/units had its own protocol for managing patients with SJS/TEN. Although this could be considered a natural experiment closer to an RCT, our decision to only consider prospective data limited the number of participants that we were able to include from this study significantly. Second, we originally planned to limit the inclusion of non‐randomised studies to those that adjusted for all our prespecified confounders. This decision would have excluded all the currently included observational studies, thus we decided it could be more informative to flag the risk of bias and include the studies instead. </p> <p>We did not find any studies addressing our main comparisons of interest. We therefore created empty summary of findings tables for them, and added four other comparisons as summary of findings based on the availability of data. </p> </section> <section id="CD013130-sec-0089"> <h3 class="title" id="CD013130-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>Due to the sparsity of prospective studies on SJS/TEN, we have looked for different strategies to provide an evidence base for clinicians. </p> <p>A previous Cochrane Review focused on TEN identified only one RCT, which found a higher mortality on TEN with thalidomide compared to placebo (<a href="./references#CD013130-bbs2-0137" title="MajumdarS , MockenhauptM , RoujeauJC , TownshendAP .Interventions for toxic epidermal necrolysis. Cochrane Database of Systematic Reviews2002, Issue 4. Art. No: CD001435. [DOI: 10.1002/14651858.CD001435]">Majumdar 2002</a>). This RCT is also included in our review. </p> <p>A review from Australia focused on studies performed in burns centres (<a href="./references#CD013130-bbs2-0094" title="MaharPD , WasiakJ , HiiB , ClelandH , WattersDA , GinD , et al.A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres. Burns2014;40(7):1245-54.">Mahar 2014</a>). They identified 20 studies, but focused on describing the different management strategies without evaluating different approaches. </p> <p><a href="./references#CD013130-bbs2-0092" title="LawEH , LeungM .Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: current evidence and implications for future research. Annals of Pharmacotherapy2015;49(3):335-42.">Law 2015</a> looked for experimental and observational studies assessing the role of corticosteroids on the management of SJS/TEN. They included six observational, retrospective studies. Only one of them showed a positive effect of corticosteroids on mortality. </p> <p><a href="./references#CD013130-bbs2-0060" title="BarronSJ , Del VecchioMT , AronoffSC .Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. International Journal of Dermatology2015;54(1):108-15.">Barron 2015</a> addressed the effect of IVIG in 13 studies, 8 with a control group, although most of them retrospective. The focus of the study was to establish whether IVIG improved standardised mortality rate. They claimed the meta‐regression showed a decrease of mortality with an increase of dose. </p> <p><a href="./references#CD013130-bbs2-0135" title="ZimmermannS , SekulaP , VenhoffM , MotschallE , KnausJ , SchumacherM , et al.Systemic immunomodulating therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a systematic review and meta-analysis. JAMA Dermatology2017;153(6):514-22.">Zimmermann 2017</a> did an exhaustive literature search of SJS/TEN studies up to 2012 evaluating mortality. They found only one RCT (the same one as <a href="./references#CD013130-bbs2-0137" title="MajumdarS , MockenhauptM , RoujeauJC , TownshendAP .Interventions for toxic epidermal necrolysis. Cochrane Database of Systematic Reviews2002, Issue 4. Art. No: CD001435. [DOI: 10.1002/14651858.CD001435]">Majumdar 2002</a>) and 157 non‐randomised studies, of which 96 were included in their analysis. They identified corticosteroids and cyclosporin as the most promising systemic immunomodulating therapies for SJS/TEN. </p> <p>A systematic review that focused on treatment of SJS/TEN in the paediatric population summarised treatment outcomes with biologics (infliximab or etanercept) in case series in 12 patients from 10 identified studies (<a href="./references#CD013130-bbs2-0113" title="SachdevaM , MuftiA , KimP , MaliyarK , SibbaldC .Biologic treatment in pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review. Journal of the American Academy of Dermatology2021;85(4):1011-3.">Sachdeva 2021</a>). The review did not provide an effect estimator for treatment with biologics.  </p> <p><a href="./references#CD013130-bbs2-0126" title="TsaiTY , HuangIH , ChaoYC , LiH , HsiehTS , WangHH , et al.Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. Journal of the American Academy of Dermatology2021;84(2):390-7.">Tsai 2021</a> performed a systematic review and network meta‐analysis focused on mortality rates and SCORTEN‐based standardised mortality ratio including 67 studies and 2079 participants. They included 10 different treatments, none of which was found to be superior to supportive care. As in our review, thalidomide was associated with a higher mortality rate. When using SCORTEN‐based standardised mortality ratio, the combination of corticosteroids and IVIG was the only treatment to show statistically significant survival benefits. It should be noted that the <a href="./references#CD013130-bbs2-0126" title="TsaiTY , HuangIH , ChaoYC , LiH , HsiehTS , WangHH , et al.Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. Journal of the American Academy of Dermatology2021;84(2):390-7.">Tsai 2021</a> authors had an unequal allocation of the groups in their network meta‐analysis, which they did not adjust for in their results or conclusions. </p> <p>All reviews agreed on the need for prospective RCTs to provide reliable answers to the effects of interventions.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013130-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Proposed pathogenesis of SJS/TEN." data-id="CD013130-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Proposed pathogenesis of SJS/TEN.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013130-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-03" target="_blank"><b></b></a></p> </div><img alt="RoB 2 summary." data-id="CD013130-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>RoB 2 summary.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias judgements for RCTs using the RoB 2 tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study." data-id="CD013130-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias judgements for RCTs using the RoB 2 tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study. " data-id="CD013130-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: SJS/TEN‐specific mortality. Follow‐up: end of study.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: time to complete re‐epithelialisation. Follow‐up: end of study. " data-id="CD013130-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-06.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: time to complete re‐epithelialisation. Follow‐up: end of study.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-06.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: total hospital length of stay. Follow‐up: end of study. " data-id="CD013130-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Risk of bias judgements for observational studies using the ROBINS‐I tool. Outcome: total hospital length of stay. Follow‐up: end of study.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Corticosteroids versus no corticosteroids, Outcome 1: Disease‐specific mortality" data-id="CD013130-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Corticosteroids versus no corticosteroids, Outcome 1: Disease‐specific mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IVIG versus no IVIG, Outcome 1: Disease‐specific mortality" data-id="CD013130-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: IVIG versus no IVIG, Outcome 1: Disease‐specific mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IVIG versus no IVIG, Outcome 2: Days to full skin healing" data-id="CD013130-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: IVIG versus no IVIG, Outcome 2: Days to full skin healing</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IVIG versus no IVIG, Outcome 3: Hospital length of stay" data-id="CD013130-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: IVIG versus no IVIG, Outcome 3: Hospital length of stay</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Etanercept versus corticosteroids, Outcome 1: Disease‐specific mortality" data-id="CD013130-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Etanercept versus corticosteroids, Outcome 1: Disease‐specific mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cyclosporin versus IVIG, Outcome 1: Disease‐specific mortality" data-id="CD013130-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Cyclosporin versus IVIG, Outcome 1: Disease‐specific mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: N‐acetylcysteine and infliximab versus infliximab alone, Outcome 1: Disease‐specific mortality" data-id="CD013130-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: N‐acetylcysteine and infliximab versus infliximab alone, Outcome 1: Disease‐specific mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Thalidomide versus placebo, Outcome 1: Disease‐specific mortality" data-id="CD013130-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Thalidomide versus placebo, Outcome 1: Disease‐specific mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013130-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/urn:x-wiley:14651858:media:CD013130:CD013130-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Plasmapheresis versus other treatments, Outcome 1: Hospital length of stay" data-id="CD013130-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_t/tCD013130-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Plasmapheresis versus other treatments, Outcome 1: Hospital length of stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/media/CDSR/CD013130/image_n/nCD013130-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Corticosteroids compared to no corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Corticosteroids compared to no corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: corticosteroids and supportive care </p> <p><b>Comparison</b>: supportive care<sup>1</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality ‐ SJS and TEN </b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> (65 to 821)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.55</b> </p> <p>(0.72 to 9.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (2 observational studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯ VERY LOW <sup>a,b</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effect estimates calculated from 1 study (<a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>). A second study did not report any events (<a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> – not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay </b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> – not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> – not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1</sup> Supportive care process in 1 study was not described (<a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a>). In the second study this was described in detail and includes topical saline compresses and sprays, petroleum jelly, bathing, topical lidocaine gel to the oral mucosa and topical antibiotics and artificial tears to the eyes (<a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a>).  </p> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of selection bias and lack of control of any confounding variables.<br/><sup>b</sup>Downgraded two levels for imprecision, as results only based on small studies, and the confidence interval includes serious harms and an important benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Corticosteroids compared to no corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous immunoglobulin (IVIG) compared to no IVIG</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) compared to no IVIG for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: IVIG and supportive care<sup>1</sup> </p> <p><b>Comparison</b>: supportive care<sup>1</sup>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SJS/TEN‐specific mortality</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(6 to 386) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.04 to 2.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An additional observational study, <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, that included a comparison of IVIG with steroids versus steroids alone did not provide useable data for meta‐analysis, but reported that “SCOR‐TEN (Score of Toxic Epidermal Necrosis) analysis showed that treatment with steroids led to an increased mortality rate, whereas treatment with IVIg decreased it". </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time to complete re‐epithelialisation was <b>10.93</b> days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>2.93 days lower</b><br/>(4.4 lower to 1.46 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An additional observational study, <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, included a comparison of IVIG with steroids versus steroids alone did not provide useable data for meta‐analysis, but reported that “The average time for complete re‐epithelialization and hospitalization was lowest in patients given IVIg and highest in those given steroids”. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>‐</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean total hospital length of stay was <b>15.33</b> days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>2.00 days lower</b><br/>(5.81 lower to 1.81 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An additional observational study, <a href="./references#CD013130-bbs2-0007" title="AgrawalP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. Allergy: European Journal of Allergy and Clinical Immunology2013;68(Suppl 97):140. SaraogiP , MahajanS , KhopkarU .Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course. British Journal of Dermatology2016;175(Suppl 1):46. ">Saraogi 2016</a>, that included a comparison of IVIG with steroids versus steroids alone did not provide useable data for meta‐analysis, but reported that “The average time for complete re‐epithelialization and hospitalization was lowest in patients given IVIg and highest in those given steroids”. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>1 </sup> <a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a> compared IVIG plus corticosteroids to supportive care plus corticosteroids.  </p> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of selection bias, as the studies were not randomised and prespecified confounders were not properly addressed, and performance bias.<br/><sup>b</sup>Downgraded two levels due to imprecision, as the confidence interval includes harms and important benefits, and results were from one small study.<br/><sup>c</sup>Downgraded one level due to imprecision, as results were from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous immunoglobulin (IVIG) compared to no IVIG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Etanercept compared to no etanercept</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to no etanercept for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: etanercept and supportive care </p> <p><b>Comparison</b>: supportive care  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies met the criteria for evaluation of etanercept to supportive care. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Etanercept compared to no etanercept</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cyclosporin compared to no cyclosporin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclosporin compared to no cyclosporin for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: cyclosporin and supportive care </p> <p><b>Comparison</b>: supportive care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with supportive care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cyclosporin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished prospective data for 22 participants were obtained from 1 cohort study, <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, for the comparison of cyclosporin versus other treatments (IVIG n = 4, corticosteroids n = 1, or no specified treatment n = 1). 4 participants died (1 on cyclosporin and 3 on IVIG) (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). Retrospective data as reported in the published paper are not included here.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cyclosporin compared to no cyclosporin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Intravenous immunoglobulin (IVIG) compared to corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin (IVIG) compared to corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: IVIG </p> <p><b>Comparison</b>: corticosteroids </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies comparing IVIG to corticosteroids.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of sta</b>y ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Intravenous immunoglobulin (IVIG) compared to corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Etanercept compared to corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital, serving as a regional referral centre for SJS/TEN cases </p> <p><b>Intervention</b>: etanercept and supportive care </p> <p><b>Comparison</b>: corticosteroids and supportive care (specifics of supportive care not identified by study) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/>(26 to 265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> </p> <p>(0.16 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported (see comments) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported that 5/48 participants in the etanercept group had serious adverse events (sepsis, respiratory failure, and bipolar disorder) and 9/43 in the corticosteroids group (sepsis, respiratory failure, upper gastrointestinal haemorrhage, stridor and vocal cord palsy) (<a href="./references#CD013130-bbs2-0008" title="WangCW , YangLY , ChenCB , HoHC , HungSI , YangCH , et al.Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation2018;128(3):985-96. ">Wang 2018</a>). It is unclear from the trial report if any of these adverse events led to discontinuation of treatment or if they were attributed to systemic therapy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision, as the confidence interval is wide and includes benefits and harms, and results were from one small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Etanercept compared to corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Cyclosporin compared to corticosteroids</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclosporin compared to corticosteroids for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: cyclosporin </p> <p><b>Comparison</b>: corticosteroids </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cyclosporin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished prospective data for 22 participants were obtained from 1 cohort study, <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, for the comparison of cyclosporin versus other treatments (IVIG n = 4, corticosteroids n = 1, or no specified treatment n = 1). 4 participants died (1 on cyclosporin and 3 on IVIG) (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). See <a href="./full#CD013130-tbl-0009">summary of findings Table 9</a> for additional details.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Cyclosporin compared to corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Etanercept compared to intravenous immunoglobulin (IVIG)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to intravenous immunoglobulin (IVIG) for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: no studies found </p> <p><b>Intervention</b>: etanercept </p> <p><b>Comparison</b>: IVIG </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IVIG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies for the comparison of etanercept to IVIG.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Etanercept compared to intravenous immunoglobulin (IVIG)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Cyclosporin compared to intravenous immunoglobulin (IVIG)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclosporin compared to intravenous immunoglobulin (IVIG) for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: inpatient hospital wards </p> <p><b>Intervention</b>: cyclosporin  </p> <p><b>Comparison</b>: IVIG  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with other treatments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cyclosporin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality </b> </p> <p>(time to follow‐up not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(10 to 468) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.13</b> </p> <p>(0.02 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1 observational study) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished prospective data for 22 participants were obtained from 1 cohort study, <a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a>, for the comparison of cyclosporin versus other treatments (IVIG n = 4, corticosteroids n = 1, or no specified treatment n = 1). 4 participants died (1 on cyclosporin and 3 on IVIG) (RR 0.13, 95% CI 0.02 to 0.98; <a href="./references#CD013130-fig-0013" title="">Analysis 4.1</a>; Fisher's exact test P = 0.046). There were 43% fewer deaths with cyclosporin compared to other treatments (95% CI 2.0% to 85.5% fewer). Retrospective data as reported in the published paper are not included here.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete re‐epithelialisation was reported only for participants treated with cyclosporin but not for other interventions. No comparison between therapies was possible. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJT/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of bias from potential confounding effects and selection bias.<br/><sup>b</sup>Downgraded one level due to imprecision, as these results were from one small study.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Cyclosporin compared to intravenous immunoglobulin (IVIG)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013130-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Etanercept compared to cyclosporin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Summary of findings:</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Etanercept compared to cyclosporin for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome </p> <p><b>Setting</b>: no studies found </p> <p><b>Intervention</b>: etanercept </p> <p><b>Comparison</b>: cyclosporin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cyclosporin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with etanercept</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific mortality</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies for the comparison of etanercept to cyclosporin.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete re‐epithelialisation</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total hospital length of stay</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects leading to discontinuation of SJS/TEN therapy</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Etanercept compared to cyclosporin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013130-tbl-0011"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>programmed cell death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epidermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>top‐most layer of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>external to the body</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fas‐mediated apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fas‐ligand belongs to a group of proteins known as tumour necrosis factor (TNF) transmembrane proteins, which are molecules present on the surfaces of skin cells. These proteins bind (connect) with receptors, which causes the skin cells to apoptose (die). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>intravenous immunoglobulin; a medical therapy that consists of concentrated antibodies extracted from the blood of healthy donors </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mucous membrane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>skin that lines internal body cavities such as the oral cavity and the vagina</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tissue death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NF‐kB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nuclear factor kappa‐light chain enhancer of activated B cells (NF‐kB) is a protein that influences DNA transcription, thereby regulating cellular responses to various stimuli. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathogenesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the mechanism (process) of a disease</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐epithelialisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the process of skin re‐growing its outermost layer (epidermis)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013130-tbl-0012"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Diagnostic criteria for Stevens‐Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as proposed by Bastuji and colleagues (1993)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Classification</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Types of lesions*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Distribution</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Percentage of body surface area detached/detachable</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bullous erythema multiforme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Typical or atypical raised targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SJS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spots ± flat atypical targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overlap SJS/TEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spots ± flat atypical targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 10 to 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TEN with spots</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spots ± flat atypical targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TEN without spots</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No spots or targets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 10</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Typical targets: lesions &lt; 3 cm with well‐defined borders and regular round shape with 3 separate zones of colour; atypical targets: flat or palpable lesions with 2 zones of colour and poorly defined borders. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Diagnostic criteria for Stevens‐Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as proposed by Bastuji and colleagues (1993)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013130-tbl-0013"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Data collection</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study information</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Citation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to initial skin healing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Date of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total duration of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age, range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to full skin healing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details of any run‐in period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concomitant medications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean hospital length of stay</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable declarations of interest of study authors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of study centres</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethnicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded medications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean intensive care unit (ICU) length of stay</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study locations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnostic criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects of treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Illness sequelae (chronic mucocutaneous morbidity)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean day of illness at which treatment was initiated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>Abbreviations:</b> SMR: standardised mortality ratio, a ratio of the observed number of deaths to the number of deaths expected for a standard population of known age and sex distribution. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Data collection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013130-tbl-0014"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: disease‐specific mortality</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of the reported result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b><a href="./references#CD013130-bbs2-0001" title="AzfarNA , ZiaMA , MalikLM , KhanAR ,  Jahangir M.Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists2010;20(3):158-62. ">Azfar 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b>  </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on most confounders ‐ unclear if comparable between groups<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided ‐ cannot determine from study text.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention status was likely determined in such a way that could have been affected by knowledge of the outcome.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in study text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data available for all reported outcomes for all participants.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.<br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0002" title="González-HerradaC , Rodríguez-MartínS , CachafeiroL , LermaV , GonzálezO , LorenteJA , et al.Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. Journal of Investigative Dermatology2017;137(10):2092-100. [PMID: 28634032]">Gonzalez‐Herrada 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most confounding variables accounted for, apart from duration of follow‐up.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All consecutive patients over the age of 14 who fulfilled diagnostic criteria during the study time period were included in the study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided on how intervention assignment took place within each burn unit. <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors provided mortality data on all prospectively recruited patients.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death was the only outcome measure of interest in this study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on some confounders ‐ unclear if comparable between study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutively diagnosed patients during the study period were included in the study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided on how intervention assignment took place other than alternate allocation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were available for all participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome was disease‐specific mortality, which is an objective measure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study assessed various outcomes of interest; this risk of bias analysis relates to disease‐specific mortality. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0005" title="KakourouT , KlontzaD , SoteropoulouF , KattamisC .Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics1997;156(2):90-3. ">Kakourou 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on most confounders ‐ unclear if comparable between study groups<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided ‐ cannot determine from text.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very few details provided on intervention groups and how group assignment took place.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear from information provided in text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific mortality is the only outcome of interest in this study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific mortality is the only outcome of interest in this study.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.<br/>  </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: disease‐specific mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013130-tbl-0015"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: days to full skin healing</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of the reported result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on some confounders ‐ unclear if comparable between study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutively diagnosed patients during the study period were included in the study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided on how intervention assignment took place, other than alternate allocation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were available for all participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concerns due to non‐blinding: evaluations and outcome measurement could have been influenced by knowledge of treatment allocation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No prespecified analysis plan was reported as finalised before unblinded data were available for analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: days to full skin healing</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013130-tbl-0016"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: hospital length of stay</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias in selection of the reported result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0003" title="HanF , ZhangJ , GuoQ , FengY , GaoY , GuoL , et al.Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. Journal of Critical Care2017;42:65-8. ">Han 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on most confounders ‐ unclear if comparable between study groups<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided ‐ cannot determine from article.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very few details provided on intervention groups and how group assignment took place: “divided into two groups on the basis of whether plasma exchange was performed after admission”.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in study text<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported on hospital length of stay for each participant in supplementary table.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information about outcome assessors and whether they were blinded was not provided.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual patient data and outcomes provided in supplementary material.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013130-bbs2-0004" title="JagadeesanS , SobhanakumariK , SadanandanSM , RavindranS , DivakaranMV , SkariaL , et al.Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian Journal of Dermatology, Venereology and Leprology2013;79(4):506-11. ">Jagadeesan 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing information on some confounders ‐ unclear if comparable between study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutively diagnosed patients during the study period were included in the study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little information provided on how intervention assignment took place, other than alternate allocation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to assess ‐ no details provided in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were available for all participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concerns due to non‐blinding: evaluations and outcome measurement could have been influenced by knowledge of treatment allocation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No prespecified analysis plan was reported as finalised before unblinded data were available for analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We assessed the study as at serious risk of bias in at least one domain, but not at critical risk of bias in any domain. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of risk of bias assessments for non‐randomised studies ‐ outcome: hospital length of stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/full#CD013130-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus no corticosteroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Disease‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.72, 9.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 SJS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.83 [0.67, 21.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 TEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.26, 11.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus no corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IVIG versus no IVIG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Disease‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Days to full skin healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Hospital length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IVIG versus no IVIG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Etanercept versus corticosteroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Disease‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Etanercept versus corticosteroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cyclosporin versus IVIG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Disease‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cyclosporin versus IVIG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">N‐acetylcysteine and infliximab versus infliximab alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Disease‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">N‐acetylcysteine and infliximab versus infliximab alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Thalidomide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Disease‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Thalidomide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013130-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Plasmapheresis versus other treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Hospital length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Plasmapheresis versus other treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#CD013130-tbl-0023">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Disease‐specific mortality</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Wang 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐allocation sequence was random and concealed: “a random number was generated by the clinical trial center... after which the investigator was given the random number and initiated the appropriate treatment” </p> <p>‐no baseline differences between intervention groups to suggest problem with randomization process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants could not be blinded. Quote: "Because the injection methods are quite different for etanercept and corticosteroids, this was not a blinded clinical trial."<br/>Carers do not seem to have been blinded. Quote: "investigator was given the random number and initiated the appropriate treatment"<br/>Nothing to suggest deviations from the intended intervention because of the trial context.<br/>All participants analysed according to the group they were assigned to.                                   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Full data reported for all participants</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐The outcomes were collected from this study are felt to be objective measures, and measurement unlikely to have differed between groups despite a lack of blinding of outcome assessors </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Mortality was not specified as an outcome in the trial registry record</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Disease‐specific mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Disease‐specific mortality</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Paquet 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Seems to be alternate allocation rather than truly random. Quote: "The patients were randomized alternatively in one of two groups", "successive randomized TEN patients"<br/>‐Illness auxiliary scores at admission are similar. No other baseline characteristics are described per group. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No mention of blinding of carers. Quote: "Each drug was administered intravenously (IV). NAC diluted in 5% glucose solution was administered at decreasing doses over a 20‐h period [...] In addition, IV infliximab was administered at a 5 mg/kg dosage as a single IV shot over a 2‐h period."<br/>No evidence to suggest any deviations from the intended intervetion because of the trial context.<br/>All participants analysed according to the group to which they were randomised and all participants received allocated intervention. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Data are available for all participants for the outcome of disease‐specific mortality.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Outcome is mortality so it would be measured the same way regardless of intervention group.<br/>‐Mortality is unlikely to have been influenced if outcome assessors were aware of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐No pre‐specified analysis plan was reported ; however, the only outcome used from this study was mortality rate which is reasonable to assume was an important outcome identified a priori as it is the most significant outcome for SJS‐TEN </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at high risk of bias in at least one domain for this result.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Disease‐specific mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Disease‐specific mortality</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Wolkenstein 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The randomisation was done in blocks of six patients stratified according to two categories of study centres—dermatological centres or burns and intensive‐care units. Two lists (one for each category of centres) were generated from tables of random numbers. These numbers were assigned to the capsule boxes. Local investigators telephoned a private randomisation service and were given an identification number that matched numbers on capsule boxes distributed in the centres. This schedule was prepared by Laboratoires Laphal; the investigators were unaware of the allocation. A set of sealed envelopes containing the code were supplied to each centre In an emergency, the code could be broken and the investigator was required to write, sign, and date an explanation." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The placebo and the thalidomide capsules were identical in appearance, and the investigators and patients did not know which capsules were given."<br/>All participants were analysed according to the group to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Although study was terminated early (due to a high death rate) prior to assessment of the study’s primary endpoint (extent of epidermal detachment at days 0, 5, 7, this outcome was not one of our pre‐specified outcomes </p> <p>‐The only outcome available from this study that was included as one of our pre‐specified outcomes was mortality, and this data was available for all participants </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐Methods for measurement of the outcome (mortality) were appropriate – this is a highly objective measure, and measurement could not have differed between groups </p> <p>‐Outcome assessors were not aware of the intervention received by study groups (blinded)</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐No pre‐specified analysis plan was reported as finalized before unblinded data were available for analysis; however, the only outcome used from this study was mortality rate which is reasonable to assume was an important outcome identified a priori as it is the most significant outcome for SJS‐TEN </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Disease‐specific mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013130.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013130.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013130-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013130-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013130-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013130-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013130-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013130-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013130-note-0013">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013130-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013130-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013130\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013130\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013130\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013130\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013130\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013130.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013130.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013130.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013130.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013130.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719998260"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013130.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719998264"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013130.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df66d79619368',t:'MTc0MDcxOTk5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 